[
  {
    "drug": "Acetaminophen (Tylenol)",
    "population": "Adult",
    "page": 230,
    "text": "For mild to moderate pain scales of 1- 5 or in moderate to severe pain where other medications are contraindicated or deferred. Tylenol, 1 gm IV/IO infusion over fifteen (15) minutes. Single dose only Acetaminophen (Tylenol) \u2013 Pediatric (ALS) For mild to moderate pain scales of 1- 5 or in moderate to severe pain where other medications are contraindicated or deferred. 2 years to 14 years: Tylenol, 15mg/kg to max of 1000mg or 1 gm IV/IO infusion over fifteen (15) minutes. Single dose only Reference #s 7010, 7020, 14100 Aden osine (Adenocard) - A dult (ALS) Stable narro w-compl ex SVT or Wide compl ex tachycardia: Adenosin e, 6 mg rapid IVP follow ed imme diately by 20 cc NS bolus, and Ade nosine, 12 mg rapid IVP follow ed immediately by 20 cc NS bolus if patient does not c onver t. May rep eat one ( 1) time. Reference # s 7010, 7020, 14040"
  },
  {
    "drug": "Albuterol (Proventil) Aerosoli zed So lution",
    "population": "Adult",
    "page": 230,
    "text": "Albut erol, 2.5 mg ne bulized, may rep eat two ( 2) times. Reference # s 4060, 7010, 7020, 14010 , 14070"
  },
  {
    "drug": "Albuterol (Proventil) Metered-Dose Inhaler (MDI)",
    "population": "Adult",
    "page": 230,
    "text": "A lbuterol MDI, f our (4) puffs every 10 minut es f or continued shortness of breath and wheezing. Reference # s 4060, 4080 , 7010, 7020, 14120, 14140, 1419 0 Albuterol (Proventil) - Ped iatric (LALS, ALS) Albut erol, 2.5 mg ne bulized, may rep eat two ( 2) times. Reference # s 7010, 7020, 14120, 14140, 14190 MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 2 of 14 Albuterol (Provent il) Metered- Dose Inhaler (M DI) - Ped iatric (BLS, LALS, ALS) Albut erol MDI, f our (4) puffs every 10 minut es f or continued shortness of breath and wheezing. Reference # s 4060, 4080 , 7010, 7020, 14120, 14140, 1419 0 Aspirin , chewab le -Adult (LALS, ALS) Aspirin, 325 mg PO chewed ( one (1) a dult non-e nteric coated a spirin) or f our (4) chewable 81 mg a spirin. Reference # s 4060, 4080 , 5010 , 7010, 7020"
  },
  {
    "drug": "Atropine (A LS)",
    "population": "Adult",
    "page": 231,
    "text": "Atropine, 1 mg IV/I O. May repeat every f ive (5) minut es up to a max imum of 3 mg or 0.04 mg/kg. Organophosphate poisoning: Atropine, 2 mg IV/IO, rep eat at 2 mg increments every f ive (5) minut es if patient remains symptoma tic. Reference # s 406 0, 4080 , 7010, 7020, 13010, 14030, 14260"
  },
  {
    "drug": "Organophosphate poisoning",
    "population": "Pediatric",
    "page": 231,
    "text": "Atropine, 0.05 mg/kg IV/IO not to exceed adult dose of 2 mg, repeat at 0.1 mg/kg increments every five (5) minutes if patient remains symptomatic . Reference #s 4060, 4080, 7010, 7020, 13010 Buprenorphine -Naloxone (Suboxone \u00ae)- Adult (ALS): Opioid Withdrawal - Clinical Opioid Withdrawal Scale \u2265 8: Buprenorphine- Naloxone, 16 mg /4mg sublingual, may repeat at 8 mg/2mg sublingual after ten (10) minutes if patient remains symptomatic, to a maximum total dose of 24 mg/6mg. Reference #s 7010, 10050"
  },
  {
    "drug": "Calcium Ch loride",
    "population": "Adult",
    "page": 231,
    "text": "Calcium Channe l Blocker Poisonings Calcium Chloride, 1 gm ( 10 ml of a 10% solution) IV/IO. Reference # s 5010, 7010, 7020, 13010 For cardiac arrest with suspected hypocalcemia, hyperkalemia, hypermagnesemia or calcium channel blocker poisoning Calcium Chloride, 1 gm (10 ml of a 10% solution) IV/IO. Reference #s 7010, 7020, 14050 MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 3 of 14 For End Stage Renal Disease (ESRD) patients on dialysis with suspected hyperkalemia and hemodynamic instability with documented sinus bradycardia,3 rd degree AV Block, 2nd degree Type II AV Block, slow junctional and ventricular escape rhythms, or slow atrial fibrillation. ( Base hospital order only). Calcium Chloride, 1 gm (10 ml of a 10% solution) IV/IO Reference #s 5010, 7010, 7020, 14030"
  },
  {
    "drug": "Calcium Chloride",
    "population": "Pediatric",
    "page": 232,
    "text": "Calcium Channel Blocker Poisonings Calcium Chloride, 20 mg/kg IV/IO over five (5) minutes. Reference #s 7010, 7020, 13010"
  },
  {
    "drug": "Hypoglycemia",
    "population": "Adult",
    "page": 232,
    "text": "Dextrose 10% /250 ml (D10W 25 gm) IV/IO Bolus Reference #s 4060, 4080 , 5010, 7010, 7020, 8010, 13020, 13030, 14040, 14060"
  },
  {
    "drug": "Dextrose",
    "population": "Pediatric",
    "page": 232,
    "text": "Hypoglycemia - Neonates (0 - 4 weeks) with blood glucose less than 35 mg/dL or pediatric patients (more than 4 weeks) with glu cose less than 60 mg/dL : Dextrose 10%/250 ml ( D10W 25 gm) 0.5 gm/kg (5 ml/k g) IV/IO Reference #s 5010, 7010, 7020, 13020, 13030, 14150 , 14160, 14170 Diazepam \u2013 Adult (ALS) only when midazolam is not commercially available. Seizures: Diazepam , 5 mg IV/IO , single dose only Diazepam 10mg IM, single dose only"
  },
  {
    "drug": "Diazepam",
    "population": "Pediatric",
    "page": 232,
    "text": "Seizures: Diazepam 0.1mg/kg IV/IO , single dose only, not to exceed adult dose of 5mg Diazepam 0.2mg/kg IM, single dose only, not to exceed adult dose of 10mg Reference #s 7010, 7020, 14170"
  },
  {
    "drug": "Diphenhydramine",
    "population": "Adult",
    "page": 232,
    "text": "Diphenhydramine, 25 m g IV/IO Diphenhydramine, 50 m g IM Reference #s 4060, 4080 , 7010, 7020, 13010, 14010"
  },
  {
    "drug": "Diphenhydramine",
    "population": "Pediatric",
    "page": 232,
    "text": "Allergic reaction: MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 4 of 14 2 years to 14 years Diphenhydramine, 1 m g/kg slow IV/IO, not to exceed adult dose of 25 mg, or Diphenhydramine, 2 m g/kg IM not to e xceed adult dose of 50 mg IM. Reference #s 7010, 7020, 14140"
  },
  {
    "drug": "Epinephrine (1 mg/ml)",
    "population": "Adult",
    "page": 233,
    "text": "Severe Bronc hospasm, Asthma Attack, Pending R espiratory Failur e, Severe Allergic Reactions: Epinephrine, 0.3 mg IM. May repeat after 15 minut es one (1) time if symptoms do not improve. Reference # 14010"
  },
  {
    "drug": "Epinephrine (0.1 mg/ml)",
    "population": "Adult",
    "page": 233,
    "text": "For p ersistent severe anaphy lactic reaction: Epinephrine (0.1 mg/ml), 0.1 mg slow IVP/IO. May repeat every five (5) minut es as needed to tot al dosage of 0.5 m g. Reference # 14010 Cardiac Arrest, As ystole, PEA: Epinephrine (0.1 mg/ml), 1 mg IV/IO. Reference #s 4060, 4080 , 5010, 7010, 7020, 14010, 14050 , 14260"
  },
  {
    "drug": "Epinephrine (0.3 Auto injector )",
    "population": "Adult",
    "page": 233,
    "text": "For severe asthma and/or anaphylaxis only Epinephrine 0.3 mg auto- injector , may repeat once after 15 minutes"
  },
  {
    "drug": "Epinephrine (0.15 Auto injector  Jr.)",
    "population": "Pediatric",
    "page": 233,
    "text": "For anaphylaxis only Epinephrine 0. 15 mg auto- injector"
  },
  {
    "drug": "Epinephrine (0.01 mg/ml)",
    "population": "Adult",
    "page": 233,
    "text": "Post resuscitation, persistent profound nontraumatic shock and hypotension, and for persistent shock due to trauma where cardiac arrest is imminent: (Push Dose Epinephrine). Prepare Epinephrine 0.01 mg/ml solution by mixing 9 ml of normal saline with 1 ml of Epinephrine 0.1 mg/ml in a 10 ml syringe. Administer 1 ml every one (1) to five (5) minutes titrated to maintain SBP more than 90 mm Hg. Reference #s 4060, 4080, 5010, 7010, 7020, 11010, 14050, 14090, 14230"
  },
  {
    "drug": "Epinephrine (1 mg/ml)",
    "population": "Pediatric",
    "page": 233,
    "text": "Severe Bronc hospasm, Asthma Attack, Pending Respiratory Failur e, Severe Allergic Reactions: MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 5 of 14 Epinephrine, 0.01 mg/kg IM not to exceed adult dos age of 0.3 mg. May repeat after 15 minut es one (1) time if symptoms do not impr ove. Reference #s 4060, 5010, 7010, 7020, 14120, 14140"
  },
  {
    "drug": "Epinephrine (0.1 mg/ml)",
    "population": "Pediatric",
    "page": 234,
    "text": "Anaphy lactic reaction (no palpable radial pulse and de pressed level of c onsciousn ess): Epinephrine (0.1 mg/ml), 0.01 mg/kg IV/IO, no more than 0.1 mg per dose. May repeat to a maximum of 0.5 mg . Cardiac Arrest: 1 day to 8 years Epinephrine (0.1 mg/ml), 0.01 mg/kg IV/IO (do not exceed adult dosage) 9 to 14 years Epinephrine (0.1 mg/ml), 1.0 mg I V/IO Newborn Care: Epinephrine (0.1 mg/ml), 0.01 mg/kg IV/IO if heart rate is less than 60 after one (1) minute after evaluating airway for hypoxia and assessing body temperature for hypother mia. Epinephrine (0.1 mg/ml), 0.005 mg/kg IV/IO every 10 minut es for persistent hypotension as a base hospital order or in radio communi cation failure. Reference # 14200"
  },
  {
    "drug": "Epinephrine (0.01 mg/ml)",
    "population": "Pediatric",
    "page": 234,
    "text": "Post r esuscitation, profound shock and hypotension, for persistent shock due to trauma where cardiac arrest is imminent (Push Dose Epinephrine): Prepare Epinephrine 0.01 mg/ml solution by mixing 9 ml of normal saline with 1 ml of Epinephrine 0.1 mg/ml in a 10 ml syringe. Administer 0.1 ml/kg (do not exceed adult dosage), every one (1) to five (5) minutes. Titrate to maintain a SBP more than 70 mm Hg. Reference #s 5010, 7010, 7020, 11010 , 14150, 14180, 14230"
  },
  {
    "drug": "Fentanyl",
    "population": "Adult",
    "page": 234,
    "text": "Chest Pain ( Presumed Ischemic Origin ): Fentanyl, 50 mcg slow IV/IO over one (1) minut e. May repeat every five (5) minut es titrated to pa in, not to e xceed 200 mc g. Fentanyl, 100 mcg IM/IN. May repeat 50 mcg every 10 minut es titrated to pain, not to exceed 200 mcg. Acute traumatic injuries, acute abdominal/flank pain, burn injuries, Cancer pain, Sickle Cell Crisis: Fentanyl, 50 mcg slow IV/IO push over one (1) minut e. May repeat every five (5) minut es titrated to pa in, not to e xceed 200 mc g IV/IO, or Fentanyl, 100 mcg IM/IN. May repeat 50 mcg every 10 minut es titrated to pain, not to exceed 200 mcg. Pacing, s ynchroniz ed cardiove rsion: Fentanyl, 50 m cg slow IV/IO ov er one (1) minut e. May repeat in five (5) minut es titrated to pa in, not to e xceed 200 mc g. MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 6 of 14 Fentanyl, 100 mc g IN. May repeat 50 mc g every 10 minut es titrated to pa in, not to exceed 200 mcg. Any combination of IV/IO/IM/IN may be a dminist ered, not to exceed 200 mcg. Contact base hospit al for additiona l orders and to dis cuss further treatment options. Reference #s 3050, 4060 , 4080 , 5010, 7010, 7020, 11020, 13030, 14070, 14090, 14100, 14240"
  },
  {
    "drug": "Fentanyl",
    "population": "Pediatric",
    "page": 235,
    "text": "Fentanyl, 0.5 mcg/kg slow IV/IO over one (1) minut e. May repeat in five (5) minut es titrated to pa in, not to e xceed 50 mcg for a single dose . Fentanyl, 1 mcg/kg IM/IN, may repeat every 10 minut es titrated to pain not to exceed 100 mcg for a single dose. Any combination of IV/IO/IM/IN may be administ ered, not to exceed four (4) doses or cumulative maximum of 200 mcg. Contact base hospit al for additiona l orders and to dis cuss further treatment options. Reference #s 3050, 4080 , 5010, 7010, 7020, 13030, 14180, 14190, 14240"
  },
  {
    "drug": "Glucose - Oral",
    "population": "Adult",
    "page": 235,
    "text": "Adult with blood glu cose less than 80 mg/d L: Glucose - Oral, one (1) tube for patients with a n intact gag reflex and hypoglycemia. Reference #s 7010, 7020, 13020, 14060, 14080, 14230"
  },
  {
    "drug": "Glucose - Oral",
    "population": "Pediatric",
    "page": 235,
    "text": "Hypoglycemia - Neonates (0 - 4 weeks) with blood glucose less than 35 mg/dL or pediatric patients (more than 4 weeks) with glu cose less than 60 mg/dL : Glucose - Oral, one (1) tube for patients with a n intact gag reflex and hypoglycemia. Reference #s 7010, 7020, 1417 0, 1416 0"
  },
  {
    "drug": "Glucagon",
    "population": "Adult",
    "page": 235,
    "text": "Glucagon, 1 mg IM/SC/IN, if unable to establish IV. May administ er one (1) time on ly. Beta blocker Poisoning (base hospita l order only): Glucagon, 1 mg IV/IO Reference #s 4060, 4080 , 7010, 7020, 13010, 13030, 14060"
  },
  {
    "drug": "Glucagon",
    "population": "Pediatric",
    "page": 235,
    "text": "Hypoglycemia, if unable to establish IV: Glucagon, 0.03 mg/kg IM/IN, if unable to start an IV. May be repeated one (1) time after 20 minut es for a combine d maximum dose of 1 mg . Reference #s 7010, 7020, 13030, 14160, 14170 MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 7 of 14 Beta blocker poisoning (base hospital order only): Glucagon, 0.03 mg/kg IV/IO Reference #\u2019s 4060, 4080, 7010, 7020, 13010 Ipratropium Bromide (Atrovent) Inhalation Solution use with Albuterol Adult (ALS) Atrovent, 0.5 mg nebulized. Administ er one (1) dose only. Reference #s 7010, 7020, 14010, 14070 Ipratropium Bromide (Atrovent) Metered-Dose Inhaler (MDI) use with Albuterol Adult (ALS) When used in combina tion with Albut erol MD I use Albut erol MDI dosing. Reference #s 4060, 4080 , 7010, 7020, 14010, 14070 Ipratropium Bromide (Atrovent) Inhalation Solution use with Albuterol - Pediatric (ALS) 1 day to 12 months Atrovent, 0.25 mg nebulized. Administ er one (1) dose only. 1 year to 14 years Atrovent, 0.5 mg nebulized. Administ er one (1) dose only. Reference #s 7010, 7020, 14120, 14140, 14190 Ipratropium Bromide (Atrovent) Metered-Dose Inhaler (MDI) use with Albuterol - Pediatric (ALS) When used in combina tion with Albut erol MD I use Albut erol MDI dosing. Reference #s 4060, 4080 , 7010, 7020, 14120, 14140, 1419 0"
  },
  {
    "drug": "Ketamine",
    "population": "Adult",
    "page": 236,
    "text": "Acute traumatic injury, acute abdominal/flank pain, burn injuries, cancer related pain and sickle cell crisis: Ketamine, 0.3 mg/kg to a max of 30 mg in a 50 - 100 ml of NS via IV over five (5) minutes. May repeat one (1) time, after 15 minutes, if pain score remains at five (5) or higher. Do not administer IVP, IO, IM, or IN. Reference #s 7010, 7020, 14100"
  },
  {
    "drug": "Lidocaine",
    "population": "Adult",
    "page": 236,
    "text": "VT (pulseless)/VF: Initial Dos e: Lidocaine, 1.5 mg /kg IV/IO For refractory VT (pulseless)/VF, may administ er an additiona l 0.75 mg/kg IV/IO, repeat one (1) time in five (5) to 10 minut es; maximum total dose of 3 mg/kg. V-Tach, Wide Compl ex Tachycardia - with Puls es: Lidocaine, 1.5 m g/kg slow IV/IO MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 8 of 14 May administ er an additional 0.75 m g/kg slow IV/IO; maximum total dose of 3 mg/kg. Reference #s 4060, 5010, 7010, 7020, 8010, 11020, 14040 , 14050 , 14090"
  },
  {
    "drug": "Lidocaine",
    "population": "Pediatric",
    "page": 237,
    "text": "Cardiac Arrest: 1 day to 8 years Lidocaine, 1.0 m g/kg IV/IO 9 to 14 years Lidocaine, 1.0 m g/kg IV/IO May repeat Lidocaine at 0.5 mg /kg after five (5) minut es; maximum total dose of 3 mg/kg. Reference #s 5010, 7010, 7020, 14150 Lidocaine 2% (Intravenous Solution) - Pediatric and Adult (ALS) Pain assoc iated with IO infusion: Lidocaine, 0.5 m g/kg slow IO push ov er two (2) minut es, not to e xceed 40 mg total. Reference #s 5010, 7010, 7020, 11020"
  },
  {
    "drug": "Magnesium Sulfate",
    "population": "Adult",
    "page": 237,
    "text": "Polymorphic Ventricular Tachycardia: Magnesium Sulfate, 2 gm IV/IO bolus over five (5) minut es for polymorphic VT if prolonged QT is observed dur ing sinus rhythm po st-cardioversion. Eclampsia (Seizure/Tonic/Clonic Activity): Magnesium Sulfate, 4 gm IV/IO slow IV push o ver three (3) to four (4) minut es. Magnesium Sulfate, 10 m g/min IV/IO drip to pr event continu ed seizures. Reference #s 5010, 7010, 7020, 8010, 14210 Severe Asthma/Respiratory Distress (ALS) (base hospital order only): Magnesium Sulfate, 2 gm slow IV drip over 20 minutes. Do not repeat. Reference# 14010"
  },
  {
    "drug": "Magnesium Sulfate",
    "population": "Pediatric",
    "page": 237,
    "text": "Severe Asthma/Respiratory Distress (base hospital order only): Magnesium Sulfate, 50 mg/kg slow IV drip over 20 minutes. Do not exceed the adult dos age of 2 gm total. Do not repeat. Reference # 14120"
  },
  {
    "drug": "Midazolam  (Versed)",
    "population": "Adult",
    "page": 237,
    "text": "Behavioral Emergencies, if patient meets criteria for potentially fatal and dangerous agitation: Midazolam, 2.5 mg IV/IO. May repeat in five (5) minutes, or Midazolam, 5 mg IM /IN. May repeat in 10 minutes. Maximum of thre e (3) dos es using a ny combination of I V/IO/IM/IN may be a dminist ered. C ontact base hospit al for addition al orders and to dis cuss further treatment options. MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 9 of 14 Reference # 14110 Post ROSC Agitation (base hospital order only): Agitation following ROSC that hinders patient\u2019s care, i.e. biting or attempting to remove ET tube/lines, Not to be used for sedation during intubation of any patients . Midazolam, 2.5 mg IV/IO or Midazolam 5 mg IM/IN Patient must have advanced airway (endotracheal tube or i -gel.) Repeat dose requires base hospital contact. Reference # 14050 Seizure: Midazolam, 2.5 mg IV/IO. May repeat in five (5) minut es for continu ed seizure activity, or Midazolam, 5 mg IM/IN. May repeat in 10 minut es for continue d seizure activity. Assess patient for medication related reduce d respiratory rate or hypotension. Maximum of thre e (3) dos es using a ny combination of I V/IO/IM/IN m ay be a dminist ered for continu ed seizure activity. Contact base hospit al for additiona l orders and to dis cuss further treatment options. Pacing, s ynchroniz ed cardiove rsion: Midazolam, 2.5 mg slow IV/IO. May repeat in five (5) minut es. Midazolam, 5 mg IM/IN. May repeat in ten (10) minut es. Maximum of thre e (3) dos es using a ny combination of I V/IO/IM/IN may be a dminist ered. C ontact base hospit al for addition al orders and to dis cuss further treatment options. CPAP: Midazolam, 1 mg IV/IO /IM/IN may be administered one (1) time for anxiety related to application of CPAP. Contact base hospital for additional or ders. Reference #s 4060, 4080 , 7010, 7020, 11020, 13020, 14060, 14210"
  },
  {
    "drug": "Midazolam  (Versed)",
    "population": "Pediatric",
    "page": 238,
    "text": "Seizures: Midazolam, 0.1 mg/kg IV/IO with maximum dose 2.5 mg. May repeat Mida zolam in f ive (5) minut es, or Midazolam, 0.2 mg/kg IM/IN with m aximum dose of 5 mg. May repeat Mida zolam in 10 minut es for continue d seizure. Assess patient for medication related reduce d respiratory rate or hypotension. Maximum of thre e (3) dos es using a ny combination of I V/IO/IM/IN m ay be a dminist ered for continu ed seizure activity. Contact base hospit al for addition al orders and to dis cuss further treatment options. MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 10 of 14 Behavioral Emergencies, if patient meets criteria for potentially fatal and dangerous agitation (base hospital order): Midazolam, 0.1 mg/kg IV/IO . May repeat in five (5) minutes, or Midazolam, 0.2 mg/kg IM/IN. May repeat in 10 minutes. Assess patient for medication related reduce d respiratory rate or hypotension. Maximum of thre e (3) dos es using a ny combination of IV/IO/IM/IN may be a dminist ered. Not to exceed adult dose. Contact base hospit al for addition al orders and to dis cuss further treatment options. Reference #s 7010, 7020, 14170, 14110"
  },
  {
    "drug": "Naloxo ne (Narcan)",
    "population": "Adult",
    "page": 239,
    "text": "For re solution of r espiratory depression r elated to susp ected opiate overdose: Naloxone, 0.5 mg IM/IN, may repeat N aloxone 0.5 mg IM/IN every two (2) to three (3) minut es if needed to improve respiratory effort . For suspected F entanyl overdose with respiratory depression: Consider a loading dose of 4 mg IN Naloxone . If no signs of respiratory improvement , consider Naloxone 0.5 mg IM/IN every two (2) to three (3) minutes if needed. Do not e xceed 10 mg of Naloxone total regardless of route administ ered. Reference #s 7010, 7020, 8030 , 14060"
  },
  {
    "drug": "Naloxo ne (Narcan)",
    "population": "Adult",
    "page": 239,
    "text": "For re solution of r espiratory depression r elated to susp ected opiate overdose: Naloxone, 0.5 mg IV/IO/IM/IN, may repeat Naloxone 0.5 mg IV/IO/IM/IN every two ( 2) to three (3) minut es if needed to improve respiratory effort . For suspected F entanyl overdose with respiratory depression: Consider a loading dose of 4 mg IN Naloxone , may repeat one (1) time. If no signs of respiratory improvement , consider Naloxone 0.5 mg IV/IO/IM/IN every two (2) to three (3) minutes if needed. Do not e xceed 10 mg of Naloxone total regardless of route administ ered. Reference #s 4080, 7010, 7020, 14060"
  },
  {
    "drug": "Naloxo ne (Narcan)",
    "population": "Pediatric",
    "page": 239,
    "text": "For re solution of r espiratory depression r elated to susp ected opiate overdose: 1 day to 8 years Naloxone, 0.1 mg/kg IM/IN (do not exceed the adult dose of 0.5 mg per administ ration) 9 to 14 years Naloxone, 0.5 mg IM/IN May repeat every two (2) to three (3) minut es if needed. Do not exceed the adult dos age of 10 mg total IM/IN. Reference #s 7010, 7020, 8030 , 14150 , 14160"
  },
  {
    "drug": "Naloxo ne (Narcan)",
    "population": "Pediatric",
    "page": 239,
    "text": "MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 11 of 14 For re solution of r espiratory depression r elated to susp ected opiate overdose: 1 day to 8 years Naloxone, 0.1 mg/kg IV/IO/IM/IN (do not exceed the adult dose of 0.5 mg per administ ration) 9 to 14 years Naloxone, 0.5 mg IV/IO/IM/IN May repeat every two (2) to three (3) minut es if needed. Do not exceed the adult dos age of 10 mg total IV/IO/IM/IN. Reference #s 7010, 7020, 14150, 14160"
  },
  {
    "drug": "Nitroglycerin (NTG)",
    "population": "Adult",
    "page": 240,
    "text": "Nitroglycerin, 0.4 m g sublin gual/transmuc osal. One (1) every three (3) minut es as needed. May be repeated as long as patient continue s to have signs of adequate tissue perfusion. If a Rig ht Ventricular Infarction is su spected , the use of nitrates requires base hospital contact. Nitroglycerin Paste, 1 inch (1 gm) transdermal , may not repeat . Nitroglycerin sublingual is the preferred route of administration for ACS. Nitro Paste is a one (1) time dose and intended for when sublingual cannot be easily administered (i .e., CPAP) . Nitroglycerin is c ontraindicated if there are signs of inadequate tissue perfusion or if sexual enhancement medications have been utilize d within the past 48 hour s. Reference #s 4060, 4080 , 7010, 7020, 14010, 14240 Ondansetron (Zofran) - Patients four (4) years old to Adult (ALS) Nausea/Vomiting: Onda nsetron, 4 mg slow IV/IO/ODT All patients four (4) to eight (8) years old: May administ er a total of 4 mgs of Onda nsetron prior to base hospit al contact. All patients nine (9) and older : May administ er Ondansetron 4 mg; may repeat two (2) tim es, at 10 m inute int ervals, for a total of 12 mgs prior to base hospit al contact. May be used as prophylactic treatm ent of nausea and vomiting associated with n arcotic administ ration. Reference #s 4080, 7010, 7020, 14090 , 14180, 14220"
  },
  {
    "drug": "Oxyg en",
    "population": "Pediatric",
    "page": 240,
    "text": "device) General Administration ( Hypoxia): Titrate Oxygen at lowest rate required to ma intain SPO 2 at 94% . Do not a dminist er suppl emental oxygen for SPO2 more than 95%. Chronic Obstruc tive Pulmonary Disease (COPD): Titrate Oxygen at lowest rate required to ma intain SPO2 at 90% . Do not a dminist er suppl emental oxygen for SPO2 more than 91%. MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 12 of 14 Reference #s 12010, 13010, 13020, 13030, 13050, 14010 , 14020 , 14030, 14040, 14060 , 14070 , 14090, 14120, 14130, 14140 , 14160, 14170, 14180, 14190, 1420 0, 14210 , 14220, 14230, 14240"
  },
  {
    "drug": "Sodium Bicarbonate",
    "population": "Adult",
    "page": 241,
    "text": "Tricyclic Poisoning (base hospital order only): Sodium Bicarbona te, 1 mEq/kg IV/IO Reference #s 5010, 7010, 7020, 13010 For cardiac arrest with suspected metabolic acidosis, hyperkalemia or tricyclic poisoning (base hospital order only): Sodium Bicarbonate, 50 mEq IV/IO / 50cc preload or 50cc single- dose vial Reference #\u2019s 7010, 7020, 14050"
  },
  {
    "drug": "Sodium Bicarbonate",
    "population": "Pediatric",
    "page": 241,
    "text": "Tricyclic Poisoning (base hospital order only): Sodium Bicarbonate, 1 mEq/kg IV/IO Reference #\u2019s 7010, 7020, 13010 Tranexamic Acid (TXA) - Patients 15 years of age and older (ALS) Signs of hemorrhagic shock meeting inclusion criteria: Administer TXA 1 gm in 50 - 100 ml of NS via IV/IO over 10 minutes. Do not administer IVP as this will cause hypotension. Signs of postpartum hemorrhagic shock (base hospital order only) Administer TXA 1 gm in 50 - 100 ml of NS via IV/IO over 10 minutes. Do not administer IVP as this will cause hypotension. Reference #s 7010, 7020, 14090, 14210, 14230, MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 13 of 14 APPENDIX I Medications for self-administration or with deployment of the ChemPack. Medications listed below may be used only for the purposes referenced by the asso ciated ICEMA Treatment Protocol. Any other use, route or dose other than those liste d, must be ordered in consultation with the Base Hospital physician."
  },
  {
    "drug": "Atropine",
    "population": "Pediatric",
    "page": 242,
    "text": "Known nerve agent/organophosphate poisoning with deployment of the ChemPack using: Two (2) or more mild symptoms: Administ er the weight-based dos e listed below as soon as an exposur e is known or strongly susp ected. If severe symptoms develop after the first dose, two (2) additiona l doses shoul d be repeated in rapid succession 10 minut es after the first dose; do not administ er more than three (3) doses. If profound anticholin ergic effects occur in the a bsence of excessive b ronchial secretions, further doses of atropine should be withheld. One (1) or more severe symptoms: Imme diately administ er (3) three weight-based doses listed below in rapid succe ssion. Weight-based dosing: Less than 6.8 kg ( less than 15 lbs ): 0.25 mg , IM usi ng multi- dose vial 6.8 to 18 kg (15 to 40 lbs ): 0.5 m g, IM usi ng AtroPen auto-injector 18 to 41 kg (40 to 90 lbs ): 1 mg , IM usi ng AtroPen auto-injector More than 41 kg ( more than 90 lbs ): 2 mg , IM usi ng multi- dose vial Symptoms of insecticide or nerve agent poisoning, as provided by manufac turer in the AtroPe n produc t labe ling, to guide therapy: Mild symptoms: Blurred vision, bradycardia, breathing di fficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nos e, salivation in creas ed, stomac h cramps, tachycardia, teary eyes, tre mor, vomitin g, or wheezing. Severe symptoms: Breathing di fficulties (severe), confused/strange behavior, defecation (involunt ary), muscular twit ching/generaliz ed weakness (severe), respiratory secretions (severe), seizure, unc onsciousne ss, u rination (involunt ary). NOTE: Infants may become drowsy or unconscious with muscle floppin ess as oppos ed to muscle twitching. Reference #s 11010, 13010, 13040"
  },
  {
    "drug": "Diazepam (Valium)",
    "population": "Adult",
    "page": 242,
    "text": "For s eizures asso ciated with nerve agent/org anophosphate exposure O NLY with the de ployment of the ChemPack: Diazepam 10 mg (5 mg/ml) auto-injector IM (if IV is un available), or Diazepam 2.5 mg IV Reference # 13040 MEDICATION - STANDARD ORDERS Reference No. 11010 Effective Date: 05/01/24 Supersedes: 11/10/23 Page 14 of 14"
  },
  {
    "drug": "Diazepam (Valium)",
    "population": "Pediatric",
    "page": 243,
    "text": "For s eizures asso ciated with nerve agent/orga nophosphate exposure ONLY with the de ployment of the ChemPack: Diazepam 0.05 m g/kg IV Reference # 13040 Nerve Agent Antidote Kit (NAA K)/Mark I or DuoDote (containing Atropine/Pralidoxime Chloride"
  },
  {
    "drug": "for self-administration or with deployment of the ChemPack)",
    "population": "Adult",
    "page": 243,
    "text": "Nerve agent exposure with assoc iated symptoms: One (1) NAAK auto-injector IM into outer thigh. May repeat up to two (2) times every 10 to 15 minutes if symptoms per sist. Reference #s 7010, 7020, 13010, 13040 INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 11020 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 4 PROCEDURE - STANDARD ORDERS 12-lead Electrocardiography (EMT -P) \u2022 ECG should be performed prior to medication administration. \u2022 ECG should be performed on any patient whose medical history and/or presenting symptoms are consistent with acute coronary syndrome including typical or atypical chest pain, syncopal episode, prior AMI, heart disease, or other associated risk factors. Capnography (EMT -P) \u2022 Utilize capnography in patients with respiratory distress, respiratory failure, cardiac arrest, and critically ill patients \u2022 Capnography is required for continuous monitoring of patients given medications that may cause respiratory depression. \u2022 Perform capnography after administration of Midazolam for behavioral emergencies. \u2022 Monitor waveform, numerical value and document in ePCR."
  },
  {
    "drug": "Continuous Positive Airway Pressure Device (CPAP)",
    "population": "Adult",
    "page": 244,
    "text": "\u2022 Start at lowest setting and increase slowly until patient experiences relief or until a maximum of 15 cm H 2O is reached. External Jugular Vein Access (AEMT and EMT -P) \u2022 Not indicated for patients eight (8) years of age and younger. \u2022 Patient condition requires IV access and other peripheral venous access attempts are unsuccessful. Blood Glucose Check (EMT, AEMT, and EMT -P) \u2022 Should be assessed if the patient meets key indicators consistent with high or low blood sugar. Intraosseous Insertion (AEMT pediatric patients only and EMT -P) \u2022 EMT -Ps may administer Lidocaine slowly per ICEMA Reference #11010 - Medication - Standard Orders, to control infusion pain. \u2022 \u2022 Approved insertion sites: \uf0d8 Eight (8) years of age or younger (LALS and ALS): \uf0a7 Proximal Tibia - Anterior medial surface of tibia, 2 cm below tibial tuberosity. PROCEDURE - STANDARD ORDERS Reference No. 11020 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 2 of 4 \uf0d8 Nine (9) years of age and older (ALS only): \uf0a7 Proximal Tibia - Anterior medial surface of tibia, 2 cm below tibial tuberosity. \uf0a7 Distal Tibia - Lower end of tibia, 2 cm above the medial malleolus. \uf0a7 Humeral Head . \uf0a7 Anterior distal femur, 2 cm above the patella - Base hospital contact only. \u2022 Leave site visible and monitor for extravasation. Nasogastric/Orogastric Tube (EMT -P) \u2022 Use a water -soluble lubricating jelly . Needle Cricothyrotomy (EMT -P) \u2022 Absolute contraindication: Transection of the distal trachea. \u2022 Monitor end- tidal CO 2 and wave form capnography. \u2022 Monitor pulse oximetry. \u2022 Contact base hospital if unable to ventilate adequately and transport immediately to the closest hospital for airway management. Needle Thoracostomy (EMT -P) \u2022 As a temporary method for chest decompression in the management of suspected tension pneumothorax. \uf0d8 Clinical Indications : \uf0a7 Patients with hypotension (SBP less than 90), clinical signs of shock, and at least one of the following signs: o Jugular vein distention. o Tracheal deviation away from the side of the injury (often a late sign). o Absent or decreased breath sounds on the affected side. o Increased resistance when ventilating a patient. \u2022 The midaxillary line at the 5th intercostal space is the preferred site. \u2022 Consider bilateral needle thoracostomy if no improvement or in traumatic cardiac arrest."
  },
  {
    "drug": "Oral Endotracheal Intubation",
    "population": "Adult",
    "page": 245,
    "text": "\u2022 Oral endotracheal intubation is permitted only in patients who are taller than the maximum length of a pediatric emergency measuring tape (Broselow, etc.) or equivalent measuring from the top of the head to the heal of the foot. \u2022 Monitor end- tidal CO 2 and wave form capnography. \u2022 Monitor pulse oximetry. PROCEDURE - STANDARD ORDERS Reference No. 11020 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 3 of 4 \u2022 If unable to place ET after a maximum of three (3) intubation attempts (defined as placement of the laryngoscope in the mouth). If unsuccessful, continue with BVM airway management and transport to the nearest receiving hospital. If BVM is ineffective then attempt placement of supraglottic airway . \u2022 Document verification of tube placement (auscultation, visualization, capnography). Supraglottic Airway \u2013Pediatric and Adult (EMT -P) \u2022 Supraglottic airway is permitted only as a B ackup airway in patients who have failed attempts with BLS airway and oral endotracheal intubation. \u2022 Monitor end- tidal CO 2 and wave form capnography. \u2022 Monitor pulse oximetry. \u2022 If unable to place after three ( 3) attempts (defined as placement of the soft gel into the mouth), continue with BLS airway and proceed to nearest receiving hospital \u2022 Document verification of SGA (auscultation, continuous capnography). Spinal Motion Restriction (EMT, AEMT and EMT -P) \u2022 Should be placed if patient meets the indicators, per ICEMA Reference #14090 - Trauma - Adult (Neuro Deficits present, Spinal Tenderness present, Altered Mental status, Intoxication, or Distracting Injury). \u2022 An AEMT and/or EMT -P may remove if placed by BLS crew and it does not meet indicators. Synchronized Cardioversion (EMT -P) \u2022 For anxiety prior to cardioversion, consider Midazolam per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 For pain, consider Fentanyl per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 If rhythm deteriorates to v-fib, turn off the sync button and defibrillate. \u2022 Select initial energy level setting at 100 joules or a clinically equivalent biphasic energy level per manufacture guidelines. Procedure may be repeated at 200, 300 and 360 joules or a clinically equivalent biphasic energy level per manufacture guidelines. \u2022 With base hospital order, repeated cardioversion attempts at 360 joules or clinically equivalent biphasic energy level per manufacturer\u2019s guidelines may be attempted. PROCEDURE - STANDARD ORDERS Reference No. 11020 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 4 of 4 Transcutaneous Cardiac Pacing (EMT -P) \u2022 Start at a rate of 60 and adjust output to the lowest setting to maintain capture. Assess peripheral pulses and confirm correlation with paced rhythm. \u2022 Reassess peripheral pulses. Adjust output to compensate for loss of capture. \u2022 Increase rate (not to exceed 100) to maintain adequate tissue perfusion. \u2022 For anxiety, consider Midazolam per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 For pain, consider Fentanyl per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Contact the base hospital if rhythm persists or for continued signs of inadequate tissue perfusion. Vagal Maneuvers (EMT -P) \u2022 Relative contraindications for patients with hypertension, suspected STEMI, or suspected head/brain injury. \u2022 Reassess cardiac and hemodynamic status. Document rhythm before, during and after procedure. \u2022 If rhythm does not covert within ten (10) seconds, follow ICEMA Reference # 14040 -"
  },
  {
    "drug": "Tachycardias",
    "population": "Adult",
    "page": 247,
    "text": "INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 12010 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 PATIENT CARE GUIDELINES I. PURPOSE To establish guidelines for the minimum standard of care and transport of patients. II. BLS INTERVENTIONS \u25cf Obtain a thorough assessment of the following: \uf0d8 Airway, breathing and circulatory status. \uf0d8 Subjective assessment of the patient\u2019s physical condition and environment. \uf0d8 Objective assessment of the patient\u2019s physical condition and environment. \uf0d8 Vital signs (blood pressure, pulse, respiration, GCS, skin signs, etc.). \uf0d8 Prior medical history and current medications. \uf0d8 Any known medication allergies or adverse reactions to medications, food or environmental agents. \u25cf Initiate care using the following tools as clinically indicated or available: \uf0d8 Spinal motion restriction . \uf0d8 Airway control with appropriate BLS airway adjunct. \uf0d8 Oxygen as clinically indicated. \uf0d8 Assist the patient into a physical position that achi eves the best medical benefit and maximum comfort. \uf0d8 Automated External Defibrillator (AED). \uf0d8 Administer Naloxone by intranasal and/or intramuscular routes. \uf0d8 Blood glucose monitoring. \uf0d8 Consider the benefits of early transport and/or intercept with ALS personnel if clinically indicated. \u25cf Assemble necessary equipment for ALS procedures or treatment under direction of EMT - P. \uf0d8 Cardiac monitoring. \uf0d8 IV/IO. \uf0d8 Endotracheal intubation. \u25cf Under EMT -P supervision, assemble pre- load medications as directed (excluding controlled substances). PATIENT CARE GUIDELINES Reference No. 12010 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 III. LIMITED ALS (LALS) INTERVENTIONS \u25cf Evaluation and continuation of all initiated BLS care. \u25cf Augment BLS assessment with an advanced assessment including, but not limited to the following: \uf0d8 Qualitative lung assessment. \uf0d8 Blood glucose monitoring. \u25cf Augment BLS treatment measures with LALS treatments as indicated by LALS protocols. \u25cf Initiate airway control as needed with the appropriate LALS adjunct. \u25cf Initiate vascular access as clinically indicated. IV. ALS INTERVENTIONS \u25cf Evaluation and continuation of all initiated BLS and/or LALS care when indicated by patient\u2019s condition. \u25cf Augment BLS and/or LALS assessment with clinically indicated advanced assessments including but not limited to the following: \uf0d8 Cardiac monitor and/or 12- lead ECG. \uf0d8 Capnography. \uf0d8 Blood glucose monitoring. \u25cf Augment BLS and/or LALS treatment with advanced treatments as clinically indicated. \uf0d8 Initiate airway control when clinically indicated using an appropriate airway adjunct to achieve adequate oxygenation and ventilation. \uf0d8 Initiate fluid resuscitation when clinically indicated. . \u25cf Review and evaluate treatments initiated by BLS, LALS, or ALS personnel. \uf0d8 Consider discontinuing treatments not warranted by patient\u2019s clinical condition. Intermittent monitoring may be used instead of continuous monitoring when clinically indicated. INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 1202 0 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 GLASGOW COMA SCALE I. EYE OPENING \u2022 Spontaneous : Eye opening is spontaneous if the patient\u2019s eyes are already open at the time of the assessment with no stimulation other than that of the existing ambient environment. The patient can close his eyes to command. This eye opening response implies an intact reticular activating mechanism and a functioning arousal mechanism. \u2022 To Voice : If the patient\u2019s eyes are not open at the time of the assessment, a response to voice is present if the eyes open when the patient\u2019s name is spoken or shouted. \u2022 To Pain : If verbal stimulation is unsuccessful in eliciting eye opening, a response to pain is present if the eyes open when a standard pain stimulus is applied. \u2022 None : No eye response is present if the above attempts at stimulation are unsuccessful. II. BEST VERBAL RESPONSE \u2022 Oriented : After being aroused, the patient is asked name, place and date. The patient is oriented if the answers given are correct. \u2022 Confused : The patient is confused if the individual cannot answer the questions regarding, name, place and date accurately, but is still capable of producing phrases, sentences or conversation exchanges. \u2022 Inappropriate : In this state, the patient cannot produce phrases, sentences or conversational exchanges, but can produce an intact word or two. These words may be electable only in response to physical stimulation and may frequently be obscenities or relative\u2019s names. \u2022 Incomprehensible : In this state, the patient can produce groans, moans or unintelligible mumblings, but cannot produce an intact word in response to stimulation. \u2022 None : In this state, the patient does not respond with any phonation to any stimulation no matter how prolonged or repeated. III. BEST MOTOR RESPONSE \u2022 Obedient: In response to instructions, whether verbal or written, or through gestures, patient shows ability to comprehend the instruction and to physically execute it. A common example is the command to hold up two fingers. \u2022 Purposeful : When a standard painful stimulus is applied, the patient may move limb or body away from stimulus in a purposeful manner or attempt to push stimulus away. \u2022 Withdrawal : If the patient does not obey commands, the standard pain stimulus is applied. Withdrawal is present if 1) the elbow flexes, 2) the movement is rapid, 3) there is no muscle stiffness and 4) the arm is drawn away from the trunk. \u2022 Flexion : Flexion is present if 1) the elbow flexes, 2) the movement is slow, 3) muscle stiffness is present, 4) the forearm and hand are held against the body and 5) the limbs hold a hemiplegic position. GLASGOW COMA SCALE Reference No. 1202 0 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 \u2022 Extension : Extension is present if 1) the legs and arms extend, 2) muscle stiffness is present and 3) external rotation of the shoulder and forearm occurs. \u2022 None : Maximum standard pain stimulation produces no motor response. NOTE: Spinal cord injury may invalidate motor assessment in this form. IV. MODIFIED GLASGOW COMA SCALE FOR INFANTS AND CHILDREN Child Infant Score Eye opening Spontaneous To speech To pain only No response Spontaneous To speech To pain only No response 4 3 2 1 Best verbal response Oriented, appropriate Confused Inappropriate words Incomprehensible sounds No response Coos and babbles Irritable cries Cries to pain Moans to pain No response 5 4 3 2 1 Best motor response* Obeys commands Localizes painful stimulus Withdraws in response to pain Flexion in response to pain Extension in response to pain No response Moves spontaneously and purposefully Withdraws to touch Withdraws to response in pain Abnormal flexion posture to pain Abnormal extension posture to pain No response 6 5 4 3 2 1 * If patient is intubated, unconscious, or preverbal, the most important part of this scale is motor response. Motor response should be carefully evaluated. INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 13010 Effective Date: 05 /01/2 4 Supersedes: 04/01/23 Page 1 of 2 POISONINGS I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Altered level of consciousness. \u2022 Signs and symptoms of substance ingestion, inhalation, injection or surface absorption. \u2022 History of substance poisoning. \u2022 For nerve agent, organophosphate or carbamate exposure in which the ChemPack has been deployed, refer to ICEMA Reference #13040 - Nerve Agent Antidote Kit (Training, Storage and Administration). II. PRIORITIES \u2022 Assure the safety of EMS field personnel, initiate decontamination and isolation procedures as indicated. \u2022 Assure and maintain ABCs. \u2022 Determine degree of physiological distress. \u2022 Obtain vital signs, history and complete physical assessment including the substance ingested, the amount, the time substance was ingested and the route. \u2022 If appropriate and can be safely transported, bring ingested substance to the hospital with patient. \u2022 Expeditious transport. III. BLS INTERVENTIONS \u2022 Assure and maintain ABCs. \u2022 Obtain oxygen saturation on room air, unless detrimental to patient condition. Administer oxygen per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Contact poison control (1- 800-222-1222). \u2022 Obtain accurate history of incident: \uf0d8 Name of product or substance. \uf0d8 Quantity ingested, and/or duration of exposure. \uf0d8 Time elapsed since exposure. \uf0d8 Pertinent medical history, chronic illness, and/or medical problems within the last twenty -four (24) hours. \uf0d8 Patient medication history. POISONINGS Reference No. 13010 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 \u2022 Obtain and monitor vital signs. \u2022 Expeditious transport. IV. LIMITED ALS (LALS) INTERVENTIONS PRIOR TO BASE HOSPITAL CONTACT \u2022 Perform activities identified in the BLS Interventions. \u2022 Obtain vascular access at a TKO rate or if signs of inadequate tissue perfusion, administer 500 cc fluid challenge and repeat until perfusion improves. \u2022 For pediatric patients with signs of inadequate tissue perfusion, administer 20 ml/kg IV and repeat until perfusion improves. V. ALS INTERVENTIONS PRIOR TO BASE HOSPITAL CONTACT \u2022 Perform activities identified in the BLS and LALS Interventions. \u2022 Monitor cardiac status. \u2022 For phenothiazine \u201cpoisoning\u201d with ataxia and/or muscle spasms, administer Diphenhydramine per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 For known organophosphate poisoning, administer Atropine per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 For seizures associated with nerve agent or organophosphate poisoning, administer Midazolam per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 For seizures associated with nerve agent or organophosphate poisoning, with deployment of the ChemPack, administer Diazepam per ICEMA Reference # 11010 - Medication - Standard Orders. VI. BASE HOSPITAL MAY ORDER THE FOLLOWING \u2022 For tricyclic poisonings, administer Sodium Bicarbonate per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 For calcium channel blocker poisonings with persistent hypotension or bradycardic arrhythmias, administer Calcium Chloride per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 For beta blocker poisonings, administer Glucagon per ICEMA Reference #11010 - Medication - Standard Orders. VII. REFERENCES Number Name 11010 Medication - Standard Orders 13040 Nerve Agent Antidote Kit (Training, Storage and Administration) INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 13020 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 4 HEAT RELATED EMERGENCIES I. FIELD ASSESSMENT/TREATMENT INDICATORS MINOR HEAT ILLNESS SYNDROMES \u2022 Environmental conditions. \u2022 Increased skin temperature. \u2022 Increased body temperature. \u2022 General weakness. \u2022 Muscle cramps. HEAT EXHAUSTION (Compensated) \u2022 All or some of the symptoms above. \u2022 Elevated temperature. \u2022 Vomiting. \u2022 Hypotension. \u2022 Diaphoresis. \u2022 Tachycardia. \u2022 Tachypnea. HEAT STROKE (Uncompensated) \u2022 All or some of the symptoms above. \u2022 Hyperthermia. \u2022 ALOC or other signs of central nervous system dysfunction. \u2022 Absence or decreased sweating. \u2022 Tachycardia. \u2022 Hypotension. HEAT EXHAUSTION/ HEAT STROKE \u2022 Dehydration. \u2022 Elevated temperature, vomiting, hypotension, diaphoresis, tachycardia and tachypnea. HEAT RELATED EMERGENCIES Reference No. 13020 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 2 of 4 \u2022 No change in LOC. HEAT RELATED EMERGENCIES Reference No. 13020 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 3 of 4 II. BLS INTERVENTIONS \u2022 Remove patient from heat source, position with legs elevated and begin cooling measures. \u2022 Oxygen as clinically indicated. \u2022 Rehydrate with small amounts of appropriate liquids as tolerated. Do not give liquids if altered level of consciousness. \u2022 If patient has signs of Heat Stroke, begin rapid cooling measures including cold packs placed adjacent to large superficial vessels. \u2022 Evaporative cooling measures. III. LIMITED ALS INTERVENTIONS \u2022 Obtain vascular access. \uf0d8 ADULT \uf0a7 Fluid bolus with 500 ml NS. Reassess and repeat fluid bolus if continued signs of inadequate tissue perfusion. \uf0d8 PEDIATRIC \uf0a7 Patients less than nine (9) years of age: Initial 20 ml/kg IV bolus; reassess and repeat fluid bolus if continued signs of inadequate tissue perfusion. \u2022 If clinically indicated, obtain blood glucose. If hypoglycemic administer: \uf0d8 ADULT/PEDIATRIC \uf0a7 Dextrose per ICEMA Reference # 11010 - Medication - Standard Orders. \uf0a7 Glucagon per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 Seizure precautions, refer to ICEMA Reference #1406 0 - Altered Level of"
  },
  {
    "drug": "Consciousness/Seizures",
    "population": "Adult",
    "page": 256,
    "text": "\u2022 Contact base hospital for destination and further treatment orders. IV. ALS INTERVENTIONS \u2022 Obtain vascular access. \uf0d8 ADULT \uf0a7 Fluid bolus with 500 ml NS. May repeat fluid bolus if continued signs of inadequate tissue perfusion. HEAT RELATED EMERGENCIES Reference No. 13020 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 4 of 4 \uf0d8 PEDIATRIC \uf0a7 Patients less than nine (9) years of age: Initial 20 ml /kg IV/IO bolus; reassess and repeat fluid bolus if continued signs of inadequate tissue perfusion. \u2022 If clinically indicated, obtain blood glucose. If hypoglycemic administer: \uf0d8 ADULT/PEDIATRIC \uf0a7 Dextrose per ICEMA Reference # 11010 - Medication - Standard Orders. \uf0a7 Glucagon per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 Base hospital may order additional medication dosages and additional fluid boluses. \u2022 Obtain rhythm strip for documentation with copy to receiving hospital. \u2022 For tonic/clonic type seizure activity administer: \uf0d8 ADULT/PEDIATRIC \uf0a7 Midazolam per ICEMA Reference # 11010 - Medication - Standard Orders. V. REFERENCES Number Name 11010 Medication - Standard Orders 1406 0 Altered Level of Consciousness/Seizures - Adult INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 13030 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 3 COLD RELATED EMERGENCIES I. FIELD ASSESSMENT/TREATMENT INDICATORS MILD HYPOTHERMIA \u2022 Decreased core temperature. \u2022 Cold, pale extremities. \u2022 Shivering, reduction in fine motor skills. \u2022 Loss of judgment and/or altered level of consciousness or simple problem solving skills. SEVERE HYPOTHERMIA \u2022 Severe cold exposure or any prolonged exposure to ambient temperatures below 36 degrees with the following indications: \uf0d8 Altered LOC with associated behavior changes. \uf0d8 Unconscious. \uf0d8 Lethargic. \u2022 Shivering is generally absent. \u2022 Blood pressure and heart sounds may be unobtainable. SUSPECTED FROSTBITE \u2022 Areas of skin that is cold, white, and hard to touch. \u2022 Capillary refill greater than two (2) seconds. \u2022 Pain and/or numbness to affected extremity. II. BLS INTERVENTIONS \u2022 Remove from cold/wet environment; remove wet clothing and dry patient. \u2022 Begin passive warming. \u2022 Insulate and apply wrapped heat packs, if available, to groin, axilla and neck. This process should be continuous. \u2022 Maintain appropriate airway with oxygen as clinically indicated (warm, humidified if possible). \u2022 Assess carotid pulse for a minimum of one (1) to two (2) minutes. If no pulse palpable, place patient on AED. If no shock advised, begin CPR. \u2022 Insulate to prevent further heat loss. COLD RELATED EMERGENCIES Reference No. 13030 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 2 of 3 \u2022 Elevate extremity if frostbite is suspected. \u2022 Do not massage affected extremity. \u2022 Wrap affected body part in dry sterile gauze to prevent further exposure and handle with extreme care. III. LIMITED ALS INTERVENTIONS \u2022 Advanced airway as clinically indicated. \u2022 Obtain vascular access. \u2022 Obtain blood glucose level, if indicated administer: \uf0d8 ADULT/PEDIATRIC \uf0a7 Dextrose per ICEMA Reference # 11010 - Medication - Standard Orders. \uf0a7 May repeat blood glucose level. Repeat Dextrose per ICEMA Reference #11010 - Medication - Standard Orders. \uf0a7 Glucagon per ICEMA Reference #11010 - Medication - Standard Orders if unable to establish IV. \u2022 Obtain vascular access and administer fluid bolus. \uf0d8 Nine (9) years and older: 500 ml warmed NS, may repeat. \uf0d8 Birth to eight (8) years: 20 ml/kg warmed NS, may repeat. \u2022 Contact base hospital. IV. ALS INTERVENTIONS \u2022 Obtain vascular access. \u2022 Cardiac monitor. \u2022 If clinically indicated, obtain blood glucose. If hypoglycemic administer: \uf0d8 ADULT/PEDIATRIC \uf0a7 Dextrose per ICEMA Reference # 11010 - Medication - Standard Orders. \uf0a7 Glucagon per ICEMA Reference #11010 - Medication - Standard Orders, if unable to establish IV. \u2022 For complaints of pain in affected body part: \uf0d8 ADULT/PEDIATRIC \uf0a7 Fentanyl per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 Advanced airway as clinically indicated. COLD RELATED EMERGENCIES Reference No. 13030 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 3 of 3 \u2022 Obtain vascular access and administer fluid bolus. \uf0d8 Nine (9) years and older: 500 ml warmed NS, may repeat. \uf0d8 Birth to eight (8) years: 20 ml/kg warmed NS, may repeat. \u2022 Obtain rhythm strip for documentation. \u2022 For documented VF, Pulseless V- Tach: \uf0d8 Defibrillate one (1) time at manufacturer recommended dose. Do not defibrillate again until patient has begun to warm. \u2022 For documented asystole: \uf0d8 Begin CPR. \uf0d8 May give additional fluid bolus. \u2022 Contact base hospital. V. REFERENCE Number Name 11010 Medication - Standard Orders INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 13040 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 NERVE AGENT ANTIDOTE KIT (TRAINING, STORAGE AND ADMINISTRATION) I. PURPOSE To provide a standard for the training, storage and use of Nerve Agent Antidote Kits (NAAKs) by EMS field personnel. II. POLICY \u2022 The NAAK (DuoDote or Mark I) is an optional personal protective equipment (PPE) for self-administration. \u2022 The NAAK is authorized for self -administration by public safety personnel, emergency medical technicians (EMTs), advanced emergency medical technicians (AEMTs) or paramedics (EMT -Ps) following exposure to nerve agents, organophosphates, or carbamates. \u2022 EMS providers equipping and employing EMTs or AEMTs with NAAKs for self - administration must provide NAAK training as described below. EMT -Ps do not require any additional training. \u2022 Public safety agencies equipping public safety personnel with NAAK s for self - administration must provide training per ICEMA Reference #15 050 - Optional Skills and Medications (Authorized Public Safety Personnel ). \u2022 When the ChemPack is deployed, EMT s, AEMT s or EMT -Ps may administer the NAAK and/or AtroPen to patients per ICEMA Reference #11010 - Medication - Standard Orders . \u2022 When the ChemPack is deployed, EMT -Ps are authorized by the ICEMA Medical Director to administer Diazepam (Valium) per ICEMA Reference -#11010 - Medication - Standard Orders. \u2022 Public s afety personnel are not permitted to administer the NAAK to patients without prior authorization (refer to ICEMA Reference #15 050 - Optional Skills and Medications (Authorized Public Safety Personnel). Public safety personnel may not administer AtroPen (Atropine). III. TRAINING REQUIREMENTS \u2022 Training will consist of no less than two (2) hours of ICEMA approved didactic and skills laboratory training that includes: \uf0d8 Indications \uf0d8 Contraindications \uf0d8 Side/adverse effects \uf0d8 Routes of administration \uf0d8 Dose \uf0d8 Mechanisms of drug action NERVE AGENT ANTIDOTE KIT (TRAINING, STORAGE AND ADMINISTRATION) Reference No. 13040 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 \uf0d8 Disposal of contaminated items and sharps \uf0d8 Medication administration and proper use of NAAK \u2022 At the completion of the training, the student will complete a competency based written and skills examination for the administration of Atropine and Pralidoxime Chloride (2-Pam) that includes: \uf0d8 Assessment of when to administer the medication. \uf0d8 Managing a patient before, during, and after administering the medication. \uf0d8 Using universal precautions and body substance isolation procedures during medication administration. \uf0d8 Demonstration of aseptic technique during medication administration. \uf0d8 Demonstrate the preparation of the medication. \uf0d8 Demonstrate site selection and administration of medication by the intramuscular route. \uf0d8 Proper disposal of contaminated items and sharps. \uf0d8 Completion of the notification of usage form. \u2022 All EMS field personnel and public safety personnel will complete the competency based skills examination every two (2) years. \u2022 EMS providers providing NAAK training must retain training records for a minimum of four (4) years and make all records available for review at the request of ICEMA or the California EMS Authority. IV. REFERENCE S Number Name 11010 Medication - Standard Orders 15050 Optional Skills and Medications (Authorized Public Safety Personnel) INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 13050 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 SMOKE INHALATION/CO EXPOSURE/SUSPECTED CYANIDE TOXICITY I. PURPOSE To identify and treat smoke inhalation and suspected cyanide toxicity. II. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Indicators \uf0d8 Exposure to fire and smoke particularly in an enclosed- space structure fires. \uf0d8 Hydrogen cyanide concentration measured in the air does not accurately correlate to patient\u2019s level of exposure and toxicity. Consider possibility of Carbon Monoxide (CO) and cyanide exposure/toxicity in any patient (or unprotected EMS field personnel) with smoke inhalation. \u2022 Cyanide Toxicity \uf0d8 Initial signs and symptoms are non- specific and may include; headache, dizziness, nausea, vomiting, confusion, and syncope. \uf0d8 Worsening signs and symptoms may include; altered level of consciousness (ALOC), hypotension, shortness of breath, seizures, cardiac dysrhythmias, and cardiac arrest. \uf0d8 The \u201cbitter almond\u201d smell on the breath of a cyanide -poisoned patient is neither sensitive nor specific and should not be considered in making the assessment. \u2022 CO Poisoning \uf0d8 Initial signs and symptoms are non- specific and may include; flu like symptoms, dizziness, severe headache, nausea, sleepiness, weakness and disorientation. \uf0d8 Worsening signs and symptoms may include; blurred vision, shortness of breath, and altered level of consciousness. III. BLS INTERVENTIONS \u2022 Remove patient from exposure area. \u2022 Administer 100% oxygen via non rebreather mask. IV. ALS INTERVENTIONS \u2022 Monitor pulse oximetry (SpO 2) though values may be unreliable in patients suffering from smoke inhalation. \u25cf Place on cardiac monitor and obtain a 12- lead ECG. \u2022 IV access, consider fluid bolus of 300 cc NS. \u2022 Use BVM with airway adjuncts as needed. Consider advanced airway if indicated. SMOKE INHALATION/CO EXPOSURE/SUSPECTED CYANIDE TOXICITY (Expanded Scope Specialty Program) Reference No. 13050 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 \u2022 For treatment of bronchospasm as indicated by wheezing, refer to ICEMA Reference #14010 - Respiratory Emergencies - Adult. \u2022 Ensure rapid transport to closest receiving emergency department. V. REFERENCE Number Name 14010 Respiratory Emergencies - Adult INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 13060 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 1 of 2 DROWNING/SUBMERSION INJURIES Cardiac arrest in drowning is caused by hypoxia, airway and ventilation are equally important to high -quality CPR. I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Submersion in water regardless of depth. \u2022 ALOC with submersion \u2022 Respiratory distress with foaming, vomiting, coughing, wheezing, abnormal lung sounds and or apnea. \u2022 Decreased or absent vital signs . II. PRIORITIES \u2022 Assure the safety of EMS field personnel . \u2022 Assure and maintain ABC s with an emphasis on reversing hypoxia. \u2022 Ventilate through the foam, do not waste time attempting to suction. \u2022 Consider trauma or pre- existing medical problem (hypoglycemia, seizure, dysrhythmia). \u2022 Assess for hypothermia. \u2022 Encourage transport even if symptoms are mild. III. BLS INTERVENTIONS \u2022 Assure and maintain ABCs. \u2022 Administer oxygen per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Maintain spinal motion restriction if indicated. \u2022 Remove wet clothing/ warm patient . \u2022 Obtain and monitor vital signs. \u2022 Provide high quality CPR if indicated with an emphasis on airway . IV. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Obtain vascular access at a TKO rate or if signs of inadequate tissue perfusion, administer 500 cc fluid challenge and repeat until perfusion improves. DROWNING/SUBMERSION INJURIES Reference No. 13060 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 2 of 2 \u2022 For pediatric patients with signs of inadequate tissue perfusion, administer 20 ml/kg IV and repeat until perfusion improves. \u2022 Administer A lbuterol per ICEMA Reference #11010- Medication- Standing Orders V. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS and LALS Interventions. \u2022 Monitor cardiac status. \u2022 Monitor end tidal CO2, pulse oximetry \u2022 Obtain glucose level. If indicated administer: \uf0d8 Dextrose per ICEMA Reference #11010- Medication -Standing Orders. \uf0d8 May repeat blood glucose level. Repeat Dextrose Per ICEMA Reference # 11010 - Medication- Standing Orders. \u2022 Administer Albuterol/Atrovent per ICEMA Reference #11010 - Medication - Stand ard Orders. \u2022 Consider an advanced airway, refer to ICEMA Reference # 11020 \u2013 Procedure - Standard Orders. VI. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure- Standing Orders 14050 Cardiac Arrest -Adult 14150 Cardiac Arrest -Pediatric INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14010 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 4 RESPIRATORY EMERGENCIES - ADULT CHRONIC OBSTRUCTIVE PULMONARY DISEASE I. FIELD ASSESSMENT/TREATMENT INDICATORS Symptoms of chronic pulmonary disease, wheezing, cough, pursed lip breathing, decreased breath sounds, accessory muscle use, anxiety, ALOC or cyanosis. II. BLS INTERVENTIONS \u2022 Reduce anxiety, allow patient to assume position of comfort. \u2022 Administer oxygen as clinically indicated, obtain oxygen saturation on room air, or on home oxygen if possible. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Maintain airway with appropriate adjuncts, including advanced airway if indicated. Obtain oxygen saturation on room air or on home oxygen if possible. \u2022 Administer Albuterol per ICEMA Reference #11010 - Medication - Standard Orders. IV. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS and LALS Interventions. \u2022 Administer Albuterol with Atrovent per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Place patient on Continuous Positive Airway Pressure (CPAP), refer to ICEMA Reference #11020 - Procedure - Standard Orders. If systolic BP remains greater than 90 mm Hg, consider Midazolam per ICEMA Reference #11010 - Medication - Standard Orders for relief of anxiety related to CPAP m ask. \u2022 Consider advanced airway, refer to ICEMA Reference #11020 - Procedure - Standard Orders. V. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure - Standard Orders. ACUTE ASTHMA/BRONCHOSPASM/ALLERGIC REACTION/ANAPHYLAXIS I. FIELD ASSESSMENT/TREATMENT INDICATORS History of prior attacks, possible toxic inhalation or allergic reaction, associated with wheezing, diminished breath sounds or cough. RESPIRATORY EMERGENCIES - ADULT Reference No. 14010 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 2 of 4 II. BLS INTERVENTIONS (For severe asthma and/or anaphylaxis only ) \u2022 Reduce anxiety, allow patient to assume position of comfort. \u2022 Administer oxygen as clinically indicated, humidified oxygen preferred. \u2022 For anaphylaxis only , administer Epinephrine (0.3 mg auto- injector) per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 May repeat Epinephrine ( 0.3 mg auto- injector ) per ICEMA Reference # 11010 - Medication - Standard Orders, after 15 minutes one (1) time. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Maintain airway with appropriate adjuncts, obtain oxygen saturation on room air if possible. \u2022 Administer Albuterol per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 For signs of inadequate tissue perfusion, initiate IV bolus of 300 ml NS. If signs of inadequate tissue perfusion persist may repeat fluid bolus one (1) time. \u2022 If no response to Albuterol, administer Epinephrine (1 mg/ml) per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 May repeat Epinephrine (1 mg/ml), per ICEMA Reference #11010 - Medication - Standard Orders, after 15 minutes one (1) time. IV. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS and LALS Interventions. \u2022 Administer Albuterol, with Atrovent per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 For suspected allergic reaction, consider Diphenhydramine per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Place patient on Continuous Positive Airway Pressure (CPAP), refer to ICEMA Reference #11020 - Procedure - Standard Orders. If systolic BP remains greater than 90 mm Hg, consider Midazolam per ICEMA Reference #11010 - Medication - Standard Orders for relief of anxiety related to CPAP mask. \u2022 If no response to Albuterol, administer Epinephrine per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 May repeat Epinephrine (1 mg/ml) per ICEMA Reference #11010 - Medication - Standard Orders after 15 minutes one (1) time. RESPIRATORY EMERGENCIES - ADULT Reference No. 14010 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 3 of 4 \u2022 For persistent severe anaphylactic reaction, administer Epinephrine (0.1 mg/ml) per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Consider advanced airway, refer to ICEMA Reference #11020 - Procedure - Standard Orders. V. BASE HOSPITAL MAY ORDER THE FOLLOWING \u2022 For severe asthma/respiratory distress that has failed to respond to the other previous treatments, administer Magnesium Sulfate per ICEMA Reference #11010 - Medication - Standard Orders. VI. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure - Standard Orders ACUTE PULMONARY EDEMA/CHF I. FIELD ASSESSMENT/TREATMENT INDICATORS History of cardiac disease, including CHF, and may present with rales, occasional wheezes, jugular venous distention and/or peripheral edema. II. BLS INTERVENTIONS \u2022 Reduce anxiety, allow patient to assume position of comfort. \u2022 Administer oxygen as clinically indicated. For pulmonary edema with high altitude as a suspected etiology, descend to a lower altitude and administer high flow oxygen with a non re- breather mask. \u2022 Be prepared to support ventilations as clinically indicated. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Maintain airway with appropriate adjuncts, obtain oxygen saturation on room air if possible. \u2022 Administer Nitroglycerine (NTG) per ICEMA Reference #11010 - Medication - Standard Orders. In the presence of hypotension (SBP less than 100), the use of NTG is contraindicated. \u2022 If symptoms do not improve after NTG administration, consider Albuterol per ICEMA Reference #11010 - Medication - Standard Orders. IV. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS and LALS Interventions. RESPIRATORY EMERGENCIES - ADULT Reference No. 14010 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 4 of 4 \u2022 Place patient on Continuous Positive Airway Pressure (CPAP), refer to ICEMA Reference #11020 - Procedure - Standard Orders. If systolic BP remains greater than 90 mm Hg, consider Midazolam per ICEMA Reference #11010 - Medication - Standard Orders for relief of anxiety related to CPAP mask. \u2022 Consider advanced airway, refer to ICEMA Reference #11020 - Procedure - Standard Orders. V. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure - Standard Orders INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14020 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 AIRWAY OBSTRUCTION - ADULT I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Universal sign of distress. \u2022 Alteration in respiratory effort and/or signs of obstruction. \u2022 Altered level of consciousness. II. BLS INTERVENTION RESPONSIVE \u2022 Assess for ability to speak or cough (e.g., \u201cAre you choking?\u201d). \u2022 If unable to speak, administer abdominal thrusts (if the rescuer is unable to encircle the victim\u2019s abdomen or the patient is in the late stages of pregnancy, utilize chest thrusts) until the obstruction is relieved or patient becomes unconscious. \u2022 After obstruction is relieved, reassess and maintain ABC\u2019s. \u2022 Administer oxygen therapy; obtain oxygen saturation. \u2022 If responsive, place in position of comfort. If uninjured but unresponsive with adequate respirations and pulse, place on side in recovery position. UNRESPONSIVE \u2022 Position patient supine (for suspected trauma, maintain in- line spinal motion restriction). \u2022 Begin immediate CPR at a 30:2 ratio for two (2) minutes. \u2022 Each time the airway is opened to ventilate, look for an object in the victim\u2019s mouth and if found, remove it. \u2022 If apneic and able to ventilate, provide one (1) breath every five (5) to six (6) seconds. \u2022 Place AED on patient. III. LIMITED ALS (LALS) INTERVENTION UNRESPONSIVE \u2022 If apneic and able to ventilate, establish advanced airway. \u2022 Establish vascular access as indicated. AIRWAY OBSTRUCTION - ADULT Reference No. 14020 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 IV. ALS INTERVENTION UNRESPONSIVE \u2022 If apneic and able to ventilate, establish advanced airway. \u2022 If obstruction persists, visualize with laryngoscope and remove visible foreign body with Magill forceps and attempt to ventilate. \u2022 If obstruction persists and unable to ventilate, consider Needle Cricothyrotomy, refer ICEMA Reference #11020 - Procedure - Standard Orders . V. REFERENCE Number Name 11020 Procedure - Standard Orders INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14030 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 1 of 2 BRADYCARDIAS - ADULT STABLE BRADYCARDIA I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Heart rate less than 60 bpm. \u2022 Signs of adequate tissue perfusion. II. BLS INTERVENTIONS \u2022 Recognition of heart rate less than 60 bpm. \u2022 Reduce anxiety, allow patient to assume position of comfort. \u2022 Administer oxygen as clinically indicated. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Establish vascular access if indicated. If lungs sound clear, consider bolus of 300 cc NS, may repeat. \u2022 Monitor and observe for changes in patient condition. IV. ALS INTERVENTIONS \u2022 Establish vascular access if indicated. If lungs sound clear, consider bolus of 300 ml NS, may repeat. \u2022 Place on cardiac monitor, obtain rhythm strip for documentation and upload to ePCR with a copy to receiving hospital. If possible, obtain a 12- lead ECG to better define the rhythm. \u2022 Monitor and observe for changes in patient condition. V. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure - Standard Orders UNSTABLE BRADYCARDIA I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Signs of inadequate tissue perfusion/shock, ALOC, or ischemic chest discomfort. II. BLS INTERVENTIONS \u2022 Recognition of heart rate less than 60 bpm. \u2022 Reduce anxiety, allow patient to assume position of comfort. BRADYCARDIAS - ADULT Reference No. 14030 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 2 of 2 \u2022 Administer oxygen as clinically indicated. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Establish vascular access if indicated by inadequate tissue perfusion. \uf0d8 Administer IV bolus of 300 ml NS, may repeat one (1) time. \uf0d8 Maintain IV rate at TKO after bolus. \u2022 Monitor and observe for changes in patient condition. IV. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS and LALS Interventions. \u2022 Place on cardiac monitor, obtain rhythm strip for documentation and upload to ePCR with a copy to receiving hospital. If possible, obtain a 12- lead ECG to better define the rhythm. \u2022 Administer Atropine per ICEMA Reference #11010 - Medication -Standard Orders. \u2022 If Atropine is ineffective, or for documented MI, 3 rd degree AV Block with wide complex and 2nd degree Type II AV Block, utilize Transcutaneous Cardiac Pacing, per ICEMA Reference #11020 Procedure - Standard Orders. \uf0d8 BASE HOSPITAL MAY ORDER THE FOLLOWING : For End Stage Renal Disease (ESRD) patients on dialysis with suspected hyperkalemia And hemodynamic instability , with documented s inus bradycardia, 3rd degree AV block and 2nd degree Type II AV Block, slow junctional and ventricular escape rhythms, or slow atrial fibrillation , administer Calcium Chloride per ICEMA Reference # 11010- Medication- Standard Order s \u2022 Contact base hospital if interventions are unsuccessful. V. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure - Standard Orders INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14040 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 TACHYCARDIAS - ADULT I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Signs and symptoms of poor perfusion. \u2022 Heart rate greater than 150 beats per minute (bpm). II. BLS INTERVENTIONS \u2022 Recognition of heart rate greater than 150 bpm. \u2022 Reduce anxiety; allow patient to assume position of comfort. \u2022 Administer oxygen as clinically indicated. \u2022 Consider transport to closest hospital or ALS intercept. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Recognition of heart rate greater than 150 bpm. \u2022 Place AED pads on patient as a precaution in the event patient has sudden cardiac arrest. \u2022 Initiate an IV with normal saline and administer 300 ml bolus to patient exhibiting inadequate tissue perfusion. \u2022 Obtain blood glucose. If indicated administer: \uf0d8 Dextrose per ICEMA Reference # 11010 - Medication - Standard Orders, or \uf0d8 Glucagon per ICEMA Reference # 11010 - Medication - Standard Orders. \uf0d8 May repeat blood glucose. Repeat Dextrose per ICEMA Reference #11010 - Medication - Standard Orders if indicated. IV. ALS INTERVENTIONS Determine cardiac rhythm, obtain a 12- lead ECG to better define rhythm if patient condition allows, establish vascular access and proceed to appropriate intervention(s). Narrow Complex Supraventricular Tachycardia (SVT) \u2022 Initiate NS bolus of 300 ml IV. \u2022 Valsalva/vagal maneuvers. \u2022 Adenosine per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 Synchronized cardioversion, refer to ICEMA Reference #11020 - Procedure - Standard Orders. TACHYCARDIAS - ADULT Reference No. 14040 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 \u2022 Contact base hospital. V-Tach or Wide Complex Tachycardias (Intermittent or Sustained) \u2022 Consider Adenosine, per ICEMA Reference # 11010 - Medication - Standard Orders, if the rate is regular and the QRS is monomorphic. Adenosine is contraindicated for unstable rhythms or if the rhythm is an irregular or polymorphic wide complex tachycardia. \u2022 If Adenosine fails to convert the rhythm or is contraindicated, consider Lidocaine per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Polymorphic VT should receive immediate unsynchronized cardioversion (defibrillation). Consider infusing Magnesium per ICEMA Reference #11010 -Medication - Standard Orders. \u2022 Precordial thump for witnessed spontaneous VT, if defibrillator is not immediately available for use. \u2022 Synchronized cardioversion, refer to ICEMA Reference #11020 - Procedure - Standard Orders. \u2022 Contact base hospital. Atrial Fib/Flutter \u2022 Transport to appropriate facility. \u2022 For patients who are hemodynamically unstable, proceed to synchronized cardioversion, refer to ICEMA Reference #11020 - Procedure - Standard Orders. \u2022 Contact base hospital. V. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure - Standard Orders INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 1405 0 Effective Date: 05/01/24 Supersedes: 04/01/23 Page 1 of 4 CARDIAC ARREST - ADULT High performance (HP) CPR is an organized approach to significantly improve the chance of survival for patients who suffer an out -of-hospital cardiac arrest (OHCA). Return of spontaneous circulation (ROSC) is resumption of sustained perfusing cardiac activity associated with significant respiratory effort after cardiac arrest. Signs of ROSC include breathing, coughing, patient movement and a palpable pulse, or a measurable blood pressure without the use of an automatic compression device. The principles for HP CPR include: \u2022 Minimize interruptions of chest compressions. \u2022 Ensure proper depth of chest compressions of 2\u201d - 2.5\u201d allowing full chest recoil (no leaning on chest). \u2022 Proper chest compression rate at 100 - 120 per minute. \u2022 Avoid compressor fatigue by rotating compressors every two (2) minutes. Ventilations shall be sufficient to cause minimal chest rise, avoiding hyperventilation as it can decrease survival. \u2022 For cardiac arrest related to drowning, refer to ICEMA Reference # 13060- Drowning/Submersion Injuries. Advanced airways can be safely delayed in OHCA patients until ROSC is achieved if the airway is effectively managed by BLS Interventions. BVM offers excellent oxygenation and ventilation without disrupting high quality compressions. Base hospital contact is not required to terminate resuscitative measures, if the patient meets criteria set forth below in the Termination of Efforts in the Prehospital Setting. I. FIELD ASSESSMENT/TREATMENT INDICATORS Cardiac arrest in a non- traumatic setting. II. BLS INTERVENTIONS \u2022 Assess patient, begin HP CPR and maintain appropriate BLS airway measures. \u2022 Place patient on AED, if available. To minimize the \u201chands off\u201d interval before a rhythm analysis/shock, complete chest compression cycle without an added pause for ventilations or pulse check just before rhythm analysis. \u2022 If shock is advised, perform HP CPR compressions while AED is charging. Remove hands from patient and deliver shock then immediately resume uninterrupted HP CPR for two (2) minutes. \u2022 Do not delay HP CPR for post -shock pulse check or a rhythm analysis. \u2022 After two (2) minutes of HP CPR, analyze rhythm using AED while checking for pulse. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform activities identified in the BLS interventions. CARDIAC ARREST - ADULT Reference No. 1405 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 2 of 4 \u2022 Establish peripheral intravenous access and administer a 500 ml bolus of normal saline (NS). \u2022 BLS airway with BVM is the airway of choice during active HP CPR. IV. ALS INTERVENTIONS \u2022 Initiate HP CPR and continue appropriate BLS Interventions while applying the cardiac monitor without interruption to chest compressions . \uf0d8 Note: Automatic compression devise may only be used for non- traumatic cardiac arrest. \u2022 Determine cardiac rhythm and defibrillate if indicated. After defibrillation, immediately began HP CPR. Begin a two (2) minute cycle of HP CPR. \u2022 Obtain IV/IO access. \u2022 BLS airways should be maintained during active CPR. Endotracheal intubation is the advanced airway of choice if BLS airway does not provide adequate ventilation. Establish advanced airway per ICEMA Reference #11020 - Procedure - Standard Orders without interruption to chest compressions. \u2022 Utilize continuous quantitative waveform capnography, for the monitoring of patients airway, the effectiveness of chest compressions and for possible early identification of ROSC. Document the waveform and the capnography number in mm HG in the ePCR. NOTE : Capnography shall be used for all cardiac arrest patients. \u2022 Insert NG/OG tube to relieve gastric distension per ICEMA Reference # 11020 - Procedure - Standard Orders. Ventricular Fibrillation/Pulseless Ventricular Tachycardia \u2022 Defibrillate at 360 joules for monophasic or biphasic equivalent per manufacture. If biphasic equivalent is unknown use maximum available. \u2022 Perform HP CPR immediately after each defibrillation for two (2) minutes, without assessing the post -defibrillation rhythm. \u2022 Administer Epinephrine per ICEMA Reference #11010 - Medication - Standard Orders every five (5) minutes, without interruption of HP CPR unless capnography indicates possible ROSC. \u2022 Reassess rhythm for no more than ten (10) seconds after each two (2) minute cycle of HP CPR. If VF/VT persists, defibrillate as above. \u2022 After two (2) cycles of HP CPR, consider administering: Lidocaine per ICEMA Reference # 11010 - Medication - Standard Orders, may repeat. \u2022 If patient remains in pulseless VF/VT after 20 minutes of CPR, consult base hospital. Pulseless Electrical Activity (PEA) or Asystole CARDIAC ARREST - ADULT Reference No. 1405 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 3 of 4 \u2022 Assess for reversible causes and initiate treatment. \u2022 Continue HP CPR with evaluation of rhythm (no more than 10 seconds) every two (2) minutes. \u2022 Administer fluid bolus of 300 ml NS IV, may repeat. \u2022 Administer Epinephrine per ICEMA Reference #11010 - Medication - Standard Orders every 5 (five) minutes without interruption of HP CPR. \u2022 Base hospital may order the following: \uf0d8 Sodium Bicarbonate per ICEMA Reference #11010 - Medication Standard Orders. \uf0d8 Calcium Chloride per ICEMA Reference #11010 - Medication Standard Orders. Stable ROSC \u2022 Obtain a 12- lead ECG, regardless of 12- lead ECG reading, transport to the closest STEMI Receiving Center, per ICEMA Reference # 9030 - Destination. \u2022 Monitor ventilation to a capnography value between 35 mm Hg and 45 mm Hg. \u2022 Utilize continuous waveform capnography to identify loss of circulation. \u2022 For persistent profound shock and hypotension, administer Push Dose Epinephrine per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Base hospital may order the following: \uf0d8 For post ROSC agitation, administer Midazolam per ICEMA Reference # 11010- Medication Standard Orders Termination of Efforts in the Prehospital Setting \u2022 The decision to terminate efforts in the field should take into consideration, first, the safety of personnel on scene, and then family and cultural considerations. \u2022 Consider terminating resuscitative efforts in the field if no ROSC is achieved and capnography waveform reading remains less than 15 mm Hg after 20 minutes of HP CPR with ALS Interventions , and any of the following criteria are met : \uf0d8 No shocks were delivered. \uf0d8 Arrest not witnessed by EMS field personnel. \uf0d8 Persistent asystole, agonal rhythm or pulseless electrical activity (PEA) at a rate of less than 40 bpm. \u2022 If patient has any signs of pending ROSC (i.e., capnography waveform trending upwards, PEA greater than 40 bpm), then consider transportation to a STEMI Receiving Center. \u2022 Contact local law enforcement to advise of prehospital determination of death. \u2022 Provide comfort and care for survivors. CARDIAC ARREST - ADULT Reference No. 1405 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 4 of 4 V. REFERENCES Number Name 9030 Destination 11010 Medication - Standard Orders 11020 Procedure - Standard Orders 13060 Drowning/Submersion Injuries INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14060 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 1 of 2 ALTERED LEVEL OF CONSCIOUSNESS/SEIZURES - ADULT I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Patient exhibiting signs/symptoms of a possible altered level of consciousness characterized by a Glasgow Coma Score of less than 15 or less than patients normal baseline. \u2022 Suspected narcotic dependence, opiate overdose, hypoglycemia, traumatic injury, shock, toxicologic, alcoholism and assess possible cardiac causes. \u2022 Tonic/clonic movements followed by a brief period of unconsciousness (post -ictal). \u2022 Suspect status epilepticus for frequent or extended seizures. \u2022 Consider carbon monoxide (CO) poisoning with any patient exposed to products of combustion. II. BLS INTERVENTIONS \u25cf Oxygen therapy as clinically indicated. If CO poisoning suspected, administer 100% oxygen via non- rebreather mask per ICEMA Reference #13050 - Smoke Inhalation/CO Exposure/Suspected Cyanide Toxicity. \u2022 Position patient as tolerated. If altered gag reflex in absence of traumatic injury, place in left lateral position. \u2022 Place patient in spinal motion restriction per ICEMA Reference #14 090 - Trauma - Adult (15 years of age and older). Obtain and assess blood glucose level. If indicated, administer Glucose - Oral per ICEMA Reference #11010 Medication - Standard Orders. \u2022 If suspected opiate overdose with severely decreased respiratory drive administer Naloxone per ICEMA Reference # 11010 - Medication - Standard Orders. \u2022 Assess patient for medication related reduced respiratory rate or hypotension. \u2022 Assess and document response to therapy. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Obtain vascular access. \u2022 Obtain and assess blood glucose level. If indicated administer: \uf0d8 Dextrose per ICEMA Reference # 11010 - Medication - Standard Orders, or \uf0d8 If unable to establish IV, Glucagon may be given one (1) time per ICEMA Reference #11010 - Medication - Standard Orders. ALTERED LEVEL OF CONSCIOUSNESS/SEIZURES - ADULT Reference No. 14060 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 2 of 2 \uf0d8 If indicated may repeat blood glucose level. Repeat Dextrose per ICEMA Reference #11010 - Medication - Standard Orders. IV. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS and LALS Interventions. \u2022 Place on cardiac monitor and obtain a 12- lead ECG. \u2022 For tonic/clonic type seizure activity, administer: \uf0d8 Midazolam per ICEMA Reference # 11010 - Medication - Standard Orders. \uf0d8 Assess patient for medication related reduced respiratory rate or hypotension. \u2022 For suspected opiate overdose with severely decreased respiratory drive, administer Naloxone per ICEMA Reference # 11010 - Medication - Standard Orders . \u2022 Assess and document response to therapy. V. REFERENCES Number Name 11010 Medication - Standard Orders 13050 Smoke Inhalation/CO exposure/Suspected Cyanide Toxicity 1409 0 Trauma - Adult (15 years of age and older) INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14070 Effective Date: 05/01/24 Supersedes: 04/01/ 23 Page 1 of 5 BURNS - ADULT (15 years of age and older) Burn patient requires effective communication and rapid transportation to the closest receiving hospital. I. FIELD ASSESSMENT/TREATMENT INDICATORS Refer to ICEMA Reference #9030 - Destination p olicy. II. BLS INTERVENTIONS \u2022 Break contact with causative agent (stop the burning process). \u2022 Remove clothing and jewelry quickly, if indicated. \u2022 Keep patient warm. \u2022 Estimate % TBSA burned and depth using the \u201cRule of Nines\u201d. \uf0d8 An individual\u2019s palm represents 1% of TBSA and can be used to estimate scattered, irregular burns. \u2022 Transport to ALS intercept or to the closest receiving hospital. A. Manage Special Considerations \u2022 Thermal Burns : Stop the burning process. Do not break blisters. Cover the affected body surface with dry, sterile dressing or sheet. \u2022 Chemical Burns : Brush off dry powder, if present. Remove any contaminated or wet clothing. Irrigate with copious amounts of saline or water. \u2022 Tar Burns : Cool with water, do not remove tar. \u2022 Electrical Burns : Remove from electrical source (without endangering self) with a nonconductive material. Cover the affected body surface with dry, sterile dressing or sheet. \u2022 Eye Involvement : Continuous flushing with NS during transport. Allow patient to remove contact lenses if possible. \u2022 Determination of Death on Scene : Refer to ICEMA Reference #1 4250 - Determination of Death On Scene. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Advanced airway as indicated. \u2022 Airway Stabilization: Burn patients with respiratory compromise or potential for such, will be transported to the closest most appropriate receiving hospital for airway stabilization. \u2022 IV access (warm IV fluids when available). BURNS - ADULT (15 years of age and older) Reference No. 14070 Effective Date: 05/01/2 4 Supersedes: 04/01/ 23 Page 2 of 5 \uf0d8 Unstable: BP less than 90 mm HG and/or signs of inadequate tissue perfusion, start 2nd IV access. IV NS 5 00 ml boluses, may repeat to a maximum of 1000 ml. \uf0d8 Stable : BP more than 90 mm HG and/or signs of adequate tissue perfusion. IV NS 5 00 ml per hour. \u2022 Transport to appropriate facility. \uf0d8 Minor Burn Classification: Transport to the closest most appropriate receiving hospital. \uf0d8 Moderate Burn Classification: Transport to the closest most appropriate receiving hospital. \uf0d8 Major Burn Classification: Transport to the closest most appropriate Burn Center (San Bernardino County contact ARMC). \uf0d8 Critical Trauma Patient (CTP) with Associated Burns: Transport to the most appropriate Trauma Center. \u2022 Burn patients with associated trauma, should be transported to the closest Trauma Center. Trauma base hospital contacted shall be made. A. Manage Special Considerations \u2022 Electrical Burns : Place AED on patient. \uf0d8 Electrical injuries that result in cardiac arrest shall be treated as medical arrests. \u2022 Respiratory Distress: Use BVM as needed and transport to the nearest facility for airway control. Contact receiving hospital ASAP. Albuterol with Atrovent per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Deteriorating Vital Signs: Transport to the closest most appropriate receiving hospital. Contact base hospital. \u2022 Pulseness and Apneic: Transport to the closest most appropriate receiving hospital and treat according to ICEMA policies. Contact base hospital. \u2022 Determination of Death on Scene : Refer to ICEMA Reference #1 4250 - Determination of Death on Scene. \u2022 Precautions and Comments : \uf0d8 High flow oxygen is essential with known or potential respiratory injury. Beware of possible smoke inhalation. \uf0d8 Contact with appropriate advisory agency may be necessary for hazardous materials, before decontamination or patient contact. BURNS - ADULT (15 years of age and older) Reference No. 14070 Effective Date: 05/01/2 4 Supersedes: 04/01/ 23 Page 3 of 5 \uf0d8 Do not apply ice or ice water directly to skin surfaces, as additional injury will result. IV. ALS INTERVENTIONS \u2022 Advanced airway (as indicated). \u2022 Airway Stabilization: Burn patients with respiratory compromise or potential for such, will be transported to the closest most appropriate receiving hospital for airway stabilization. \u2022 Monitor ECG. \u2022 IV/IO Access (Warm IV fluids when available). \uf0d8 Unstable: BP less than 90 mm HG and/or signs of inadequate tissue perfusion, start 2 nd IV access. IV/IO NS 500 ml boluses, may repeat to a maximum of 1000 ml. \uf0d8 Stable : BP more than 90 mm HG and/or signs of adequate tissue perfusion. IV/IO NS 500 ml per hour. \u2022 Treat pain as indicated. Pain Relief : Administer an appropriate analgesic per ICEMA Reference #1410 0 - Pain"
  },
  {
    "drug": "Management",
    "population": "Adult",
    "page": 285,
    "text": "arrival at destination. \u2022 Transport to appropriate facility: \uf0d8 CTP with associated burns, transport to the closest Trauma Center. \uf0d8 Burn patients with associated trauma, should be transported to the closest Trauma Center. Trauma base hospital contacted shall be made. \u2022 Insert nasogastric/orogastric tube as indicated. \u2022 Refer to Section V - Burn Classifications below. A. Manage Special Considerations \u2022 Electrical Burns : Monitor for dysrhythmias, treat according to ICEMA protocols. \uf0d8 Electrical injuries that result in cardiac arrest shall be treated as medical arrests. \u2022 Respiratory Distress: Intubate patient if facial/oral swelling are present or if respiratory depression or distress develops due to inhalation injury. \uf0d8 Albuterol with Atrovent per ICEMA Reference # 11010 - Medication - Standard Orders. BURNS - ADULT (15 years of age and older) Reference No. 14070 Effective Date: 05/01/2 4 Supersedes: 04/01/ 23 Page 4 of 5 \uf0d8 Administer humidified oxygen, if available. \uf0d8 Apply capnography. \uf0d8 Awake and breathing patients with potential for facial/inhalation burns are not candidates for nasal tracheal intubation. CPAP may be considered, if indicated, after consultation with base hospital. \u2022 Deteriorating Vital Signs : Transport to the closest receiving hospital. Contact base hospital. \u2022 Pulseness and Apneic: Transport to the closest receiving hospital and treat according to ICEMA policies. Contact base hospital. \u2022 Determination of Death on Scene : Refer to ICEMA Reference #14250 - Determination of Death on Scene. \u2022 Precautions and Comments : \uf0d8 Contact with appropriate advisory agency may be necessary for hazardous materials, before decontamination or patient contact. \uf0d8 Do not apply ice or ice water directly to skin surfaces, as additional injury will result. \u2022 Base Hospital Orders: May order additional medications, fluid boluses and CPAP. V. BURN CLASSIFICATIONS ADULT BURN CLASSIFICATION CHART DESTINATION MINOR - ADULT \u2022 Less than 10% TBSA \u2022 Less than 2% Full Thickness CLOSEST MOST APPROPRIATE RECEIVING HOSPITAL MODERATE - ADULT \u2022 10 - 20% TBSA \u2022 2 - 5% Full Thickness \u2022 High Voltage Burn \u2022 Suspected Inhalation Injury \u2022 Circumferential Burn \u2022 Medical problem predisposing to infection (e.g., diabetes mellitus, sickle cell disease) CLOSEST MOST APPROPRIATE RECEIVING HOSPITAL BURNS - ADULT (15 years of age and older) Reference No. 14070 Effective Date: 05/01/2 4 Supersedes: 04/01/ 23 Page 5 of 5 VI. REFERENCES Number Name 9030 Destination 11010 Medication - Standard Orders 14100 Pain Management - Adult 1425 0 Determination of Death on Scene MAJOR - ADULT \u2022 More than 20% TBSA burn in adults \u2022 More than 5% Full Thickness \u2022 Known Inhalation Injury \u2022 Any significant burn to face, eyes, ears, genitalia, or joints CLOSEST MOST APPROPRIATE BURN CENTER In San Bernardino County, contact: Arrowhead Regional Medical Center (ARMC) \u201cRule of Nines\u201d INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14080 Effective Date: 05/01/24 Supersedes: 04/01/23 Page 1 of 3 STROKE TREATMENT - ADULT I. FIELD ASSESSMENT/TREATMENT INDICATORS Patient exhibiting signs/symptoms of a possible stroke. These signs may include: speech disturbances, altered level of consciousness, parasthesias, new onset seizures, dizziness unilateral weakness and visual disturbances. II. BLS INTERVENTIONS \u2022 Obtain patient oxygen saturation on room air. Titrate oxygen if clinically indicated, to maintain an oxygen saturation of 94% per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Obtain blood glucose. III. LIMITED ALS (LALS)/ALS INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Obtain vascular access. \u2022 Modified Los Angeles County Prehospital Stroke Screen (mLAPSS): A screening tool used by EMS field personnel to assist in identifying patients who may be having a stroke. mLAPSS Criteria : The patient is mLAPSS positive , if \u201cyes\u201d on Criteria #1 - 4 and exhibits unilateral weakness on Criteria #6. mLAPSS Criteria Yes No 1. Age over 17 years? 2. No prior history of seizure disorder? 3. New onset of neurologic symptoms in last 24 hours? 4. Patient was ambulatory at baseline prior to event? 5. Blood glucose between 60 and 400? 6. Exam ( look for obvious asymmetry): Normal - Bilaterally Right Left \u2022 Facial Smile/Grimace \u0000 \u0000 Droop \u0000 Normal \u0000 Droop \u0000 Normal \u2022 Grip \u0000 \u0000 Weak Grip \u0000 Normal \u0000 Weak Grip \u0000 Normal \u0000 \u0000 No Grip \u0000 Normal \u0000 No Grip \u0000 Normal \u2022 Arm Weakness \u0000 \u0000 Drifts Down \u0000 Normal \u0000 Drifts Down \u0000 Normal \u0000 Falls Down Rapidly \u0000 Normal \u0000 Falls Down Rapidly \u0000 Normal STROKE TREATMENT - ADULT Reference No. 14080 Effective Date: 05/01/2 4 Supersedes: 04/01/2 3 Page 2 of 3 \u2022 If patient is mLAPSS positive, use LAMS to determine the stroke severity. \u2022 Patients less than 17 years of age presenting as a suspected stroke, consider transporting to the closest stroke center. \u2022 Los Angeles Motor Score (LAMS): A scoring tool used by EMS providers to determine the severity of stroke on patients who are mLAPSS positive. If the total LAMS score is four (4) or greater, consider Large Vessel Occlusion (LVO). LAMS Score Criteria FACE 0 Both sides move normally 1 One side is weak or flaccid ARM 0 Both sides move normally 1 One side is weak 2 One side is flaccid/does not move GRIP 0 Both sides move normally 1 One side is weak 2 One side is flaccid/does not move TOTAL SCORE \u2022 Ask when \u201clast seen normal\u201d or without stroke symptoms. \u2022 If \u201clast seen normal\u201d plus transport time is less than 24 hours, or a \u201cwake- up stroke\u201d, transport to closest Stroke Receiving Center. \u2022 If \u201clast seen normal\u201d plus transport time is greater than 24 hours, transport to the closest receiving hospital. \u2022 If mLAPSS negative and stroke is still suspected, consult base hospital for destination. \u2022 To ensure that there is no delay in treatment obtain and document on scene family phone number. \uf0d8 If family member is not present, it is recommended that the EMS field personnel bring the patients cell phone. \u2022 Consider 12- lead ECG (ALS only). \u2022 Thrombolytic Assessment : If time is available, and the patient or family can provide the information, assess the patient using the criteria listed below and report to ED personnel: Thrombolytic Assessment Criteria Yes No Onset greater than 4.5 hours? History of recent bleeding? Use of anticoagulant? Major surgery or serious trauma in the previous 14 days? Sustained systolic blood pressure above 185 mm Hg? Recent stroke or intracranial hemorrhage? IV. REFERENCE Number Name STROKE TREATMENT - ADULT Reference No. 14080 Effective Date: 05 /01/2 4 Supersedes: 04/01/2 3 Page 3 of 3 11010 Medication - Standard Orders INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 1 of 7 TRAUMA - ADULT (15 years of age and older) I. FIELD ASSESSMENT/TREATMENT INDICATORS \u2022 Any trauma patient meeting Trauma Triage Criteria requiring rapid transportation to the closest Trauma Center . \u2022 Refer to ICEMA Reference #9040 - Trauma Triage Criteria and ICEMA Reference #9030 - Destination. \u2022 Contact the Trauma Center as soon as possible in order to activate the trauma team. \uf0d8 If the closest Trauma Center is outside ICEMA region, and no base orders or consult is needed, EMS field personnel may contact the hospital they will be transporting the patient to. \uf0d8 In Inyo and Mono Counties, the assigned base hospital shall be contacted for determination of appropriate destination. NOTE : EMS field personnel are not authorized to evaluate patients with suspected concussion for purpose of return to play clearance. II. BLS INTERVENTIONS \u2022 Ensure thorough initial assessment. \u2022 Ensure patent airway, protecting cervical spine. \u2022 Obtain oxygen saturation (if BLS equipped). \u2022 Administer oxygen and/or ventilate as needed. \u2022 Keep patient warm. \u2022 For a traumatic full arrest, provide CPR, utilize the AED if indicated and transport to the closest most appropriate hospital . \u2022 Mechanical cardiopulmonary resuscitation (mCPR) devices are contraindicated for trauma patients \u2022 Transport to ALS intercept or to the closest receiving hospital. A. Manage Special Considerations \u2022 Spinal Motion Restriction : If the patient meet(s) any of the following indicators using the acronym (NSAID): N-euro Deficit(s) present? S-pinal Tenderness present? A-ltered Mental Status? I-ntoxication? D-istracting Injury? TRAUMA - ADULT (15 years of age and older) Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 2 of 7 \uf0d8 Consider maintaining spinal alignment on the gurney, or using spinal motion restriction on an awake, alert and cooperative patient, without the use of a rigid spine board. \uf0d8 Penetrating trauma without any NSAID indicators are not candidates for spinal motion restriction . NOTE : The long backboard (LBB) is an extrication tool, whose purpose is to facilitate the transfer of a patient to a transport stretcher and is not intended, or appropriate for achieving spinal motion restriction. Judicious application of the LBB for purposes other than extrication necessitates that EMS field personnel ensure the benefits outweigh the risks. If a LBB is applied for any reason, patients should be removed as soon as it is safe and practical. LBB does not need to be reapplied on interfacility transfer (IFT) patients. \u2022 Abdominal Trauma : Cover eviscerated organs with saline dampened gauze. Do not attempt to replace organs into the abdominal cavity. \u2022 Amputations : Control bleeding. Rinse amputated part gently with sterile irrigation saline to remove loose debris/gross contamination. Place amputated part in dry, sterile gauze and in a plastic bag surrounded by ice (if available). Prevent direct contact with ice. Document in the narrative who the amputated part was given to. Partial Amputation : Splint in anatomic position and elevate the extremity. \u2022 Bleeding : \uf0d8 Apply direct pressure and/or pressure dressing. \uf0d8 When direct pressure or pressure dressing fails , control life threatening bleeding of a severely injured extremity with the application of a tourniquet . \u2022 Chest Trauma : If a wound is present, cover it with an occlusive dressing. If the patient\u2019s ventilations are being assisted, dress wound loosely, (do not seal). Continuously reevaluate patient for the development of tension pneumothorax. \u2022 Flail Chest : Stabilize chest, observe for tension pneumothorax. Consider assisted ventilations. \u2022 Fractures : Immobilize above and below the injury. Apply splint to injury in position found except: \uf0d8 Femur : Apply traction splint if indicated. \uf0d8 Grossly angulated long bone with distal neurovascular compromise : Apply gentle unidirectional traction to improve circulation. \uf0d8 Check and document distal pulse before and after positioning . \u2022 Genital Injuries : Cover genitalia with saline soaked gauze. If necessary, apply direct pressure to control bleeding. Treat amputations the same as extremity amputations. TRAUMA - ADULT (15 years of age and older) Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 3 of 7 \u2022 Head and Neck Trauma: Place brain injured patients in reverse Trendelenburg (elevate the head of the backboard 15 - 20 degrees), if the patient exhibits no signs of shock. \uf0d8 Eye: Whenever possible protect an injured eye with a rigid dressing, cup or eye shield. Do not attempt to replace a partially torn globe, stabilize it in place with sterile saline soaked gauze. Cover uninjured eye. \uf0d8 Avulsed Tooth : Collect teeth, place in moist, sterile saline gauze and place in a plastic bag. \u2022 Impaled Object : Immobilize and leave in place. Remove object if it interferes with CPR, or if the object is impaled in the face, cheek or neck and is compromising ventilations. \u2022 Determination of Death on Scene : Refer to ICEMA Reference #1 4250 - Determination of Death on Scene. III. LIMITED ALS (LALS) INTERVENTIONS \u2022 Perform identified BLS interventions and additional LALS interventions. \u2022 Advanced airway (as indicated). \uf0d8 Unmanageable Airway: Transport to the closest most appropriate receiving hospital when the patient requires advanced airway and an adequate airway cannot be maintained with a BVM device. \u2022 Establish IV access. \uf0d8 Unstable: If BP less than 90 mm Hg and/or signs of inadequate perfusion, start 2nd IV access. \uf0d8 Stable : Maintain IV if BP more than 90 mm Hg and/or signs of adequate tissue perfusion. Blunt Trauma : \uf0d8 Unstable: Establish IV NS administer 250 ml bolus. May repeat one (1) time to a maximum of 500 ml . \uf0d8 Stable : Saline lock only, do not administer IV fluids . Penetrating Trauma : \uf0d8 Saline lock only, do not administer IV fluids. Isolated Closed Head Injury: \uf0d8 Unstable: Establish IV NS, administer 250 ml bolus. May repeat one (1) time to a maximum of 500 ml. \uf0d8 Stable : Saline lock only, do not administer IV fluids. TRAUMA - ADULT (15 years of age and older) Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 4 of 7 Isolated Extremity Trauma: \uf0d8 Unstable: Establish IV NS, administer 250 ml bolus. May repeat one (1) time to a maximum of 500 ml. \uf0d8 Stable : Saline lock only, do not administer IV fluids. \u2022 Transport to appropriate hospital. A. Manage Special Considerations \u2022 Consider Push Dose Epi for persistent shock due to trauma where cardiac arrest is imminent, per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Spinal Motion Restriction: LALS personnel should remove LBB devices from patients placed in full spinal motion restriction precautions by first responders and BLS personnel if the patient does not meet any of the following indicators using the acronym (NSAID): N-euro Deficit(s) present? S-pinal Tenderness present? A-ltered Mental Status? I-ntoxication? D-istracting Injury? \u2022 Impaled Object : Remove object upon Trauma base hospital physician order, if indicated. B. Determination of Death on Scene : Refer to ICEMA Reference # 14250 - Determination of Death on Scene. \u2022 Severe Blunt Force Trauma Arrest : If indicated, transport to the closest receiving hospital. \u2022 Penetrating Trauma Arrest : If indicated, transport to the closest receiving hospital. \u2022 If the patient does not meet the \u201cObvious Death Criteria\u201d per ICEMA Reference #14250 - Determination of Death on Scene, contact the T rauma base hospital for determination of death on scene for those patients who suffer a traumatic cardiac arrest in the setting of penetrating trauma and no reported vital signs (palpable pulse and/or spontaneous respirations) during the EMS encounter with the patient. \u2022 Resuscitation efforts on a penetrating traumatic arrest victim are not to be terminated without Trauma base hospital contact. \u2022 Precautions and Comments : \uf0d8 Electrical injuries that result in cardiac arrest shall be treated as medical arrests. \uf0d8 Consider cardiac etiology in older patients in cardiac arrest with low probability of mechanism of injury. TRAUMA - ADULT (15 years of age and older) Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 5 of 7 \uf0d8 If the patient is not responsive to trauma- oriented resuscitation, consider medical etiology and treat accordingly. \uf0d8 Unsafe scene may warrant transport despite low potential for survival. IV. ALS INTERVENTIONS \u2022 Perform identified BLS and LALS intervention and t he additional ALS interventions. \u2022 Advanced Airway (as indicated): \uf0d8 Unmanageable Airway: If an adequate airway cannot be maintained with a BVM device; and the paramedic is unable to intubate or insert SGA or perform a successful needle cricothyrotomy (if indicated), then transport to the closest receiving hospital and follow ICEMA Reference # 9010 - Continuation of Care (San Bernardino County Only) . \u2022 Monitor ECG. \u2022 Establish IV/IO access. \uf0d8 Unstable: If BP less than 90 mm Hg and/or signs of inadequate perfusion, start 2 nd IV access. \uf0d8 Stable : Maintain IV /IO if BP more than 90 mm Hg and/or signs of adequate tissue perfusion. Blunt Trauma : \uf0d8 Unstable: Establish IV /IO NS administer 250 ml bolus. May repeat one (1) time to a maximum of 500 ml. \uf0d8 Stable : Saline lock only, do not administer IV fluids . Penetrating Trauma : \uf0d8 Saline lock only, do not administer IV fluids. Isolated Closed Head Injury: \uf0d8 Unstable: Establish IV /IO NS, administer 250 ml bolus. May repeat one (1) time to a maximum of 500 ml. \uf0d8 Stable : Saline lock only, do not administer IV fluids. Isolated Extremity Trauma: \uf0d8 Unstable: Establish IV /IO NS, administer 250 ml bolus. May repeat one (1) time to a maximum of 500 ml (avoid placement on injured extremity) . \uf0d8 Stable : Saline lock only, do not administer IV fluids. \u2022 Tranexamic Acid (TXA) administration for blunt or penetrating traumas : TRAUMA - ADULT (15 years of age and older) Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 6 of 7 \uf0d8 Must be within three (3) hours of injury and must have either: \uf0a7 Signs and symptoms of hemorrhagic shock with SBP less than 9 0 mm Hg. \uf0a7 Significant hemorrhage with heart rate greater than or equal to 120. \uf0a7 Bleeding not controlled by direct pressure or tourniquet. \uf0a7 Pediatric administration is not indicated. \uf0d8 Blunt Trauma : \u25aa For signs of hemorrhagic shock meeting inclusion criteria above, administer TXA per ICEMA Reference #11010 - Medication - Standard Orders. \uf0d8 Penetrating Trauma : \u25aa For signs of hemorrhagic shock meeting inclusion criteria above, administer TXA per ICEMA Reference #11010 - Medication - Standard Orders. \u2022 Transport to appropriate Trauma Center . \u2022 Insert nasogastric/orogastric tube as indicated. A. Manage Special Considerations \u2022 As a temporary method for chest decompression, in the management of suspected tension pneumothorax, p erform needle thoracostomy . \uf0d8 Clinical Indications: o Patients with hypotension (SBP less than 90), clinical signs of shock, and at least one of the following signs: o Jugular vein distention. o Tracheal deviation away from the side of the injury (often a late sign). o Absent or decreased breath sounds on the affected side. o Increased resistance when ventilating a patient \u2022 The midaxillary line at the 5th intercostal space is the preferred site. . \u2022 Consider bilateral needle thoracostomy if no improvement or in traumatic cardiac arrest. \u2022 Pain Relief for Acute Traumatic Injuries : \uf0d8 Administer an appropriate analgesic per ICEMA Reference #14100 - Pain Management. Document vital signs and pain scales every five (5) minutes until arrival at destination \uf0d8 Consider Ondansetron per ICEMA Reference # 11010 - Medication - Standard Orders. TRAUMA - ADULT (15 years of age and older) Reference No. 1409 0 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 7 of 7 B. Determination of Death on Scene : Refer to ICEMA Reference #1 4250 - Determination of Death on Scene. \u2022 Severe Blunt Force Trauma Arrest : If indicated, pronounce on scene. \u2022 Penetrating Trauma Arrest : If indicated, transport to the closest receiving hospital. \u2022 If the patient does not meet the \u201cObvious Death Criteria\u201d per ICEMA Reference #14250 - Determination of Death on Scene, contact the Trauma base hospital for determination of death on scene for those patients who suffer a traumatic cardiac arrest in the setting of penetrating trauma with documented asystole in at least two (2) leads, and no reported vital signs (palpable pulse and/or spontaneous respirations) during the EMS encounter with the patient. V. REFERENCES Number Name 9010 Continuation of Care 9030 Destination 9040 Trauma Triage Criteria 11010 Medication - Standard Orders 14050 Cardiac Arrest - Adult 14100 Pain Management 14250 Determination of Death on Scene INLAND COUNTIES EMERGENCY MEDICAL AGENCY POLICY AND PROTOCOL MANUAL Reference No. 14100 Effective Date: 05/01/24 Supersedes: 04/01/23 Page 1 of 2 PAIN MANAGEMENT I. PURPOSE To define the prehospital use of analgesics for pain management to patients with mild to severe pain. II. FIELD ASSESSMENT/TREATMENT INDICATORS The prehospital use of analgesics should be considered for the following: \u2022 Acute traumatic injuries \u2022 Acute abdominal/flank pain \u2022 Burn injuries \u2022 Cancer pain \u2022 Sickle Cell Crisis \uf0d8 The inability to recall a specific traumatic incident does not necessarily preclude the administration of pain medication . III. BLS INTERVENTIONS \u2022 Attempt to calm, reduce anxiety, and allow patient to assume position of comfort. \u2022 Utilize ice, immobilize and splint the affected area as indicated. \u2022 Assess patients level of pain using the pain scale from 1 - 10 with 10 being the worst pain. \u2022 Administer oxygen as clinically indicated per ICEMA Reference # 12010 - Patient Care Guidelines. IV. ALS INTERVENTIONS \u2022 Perform activities identified in the BLS Interventions. \u2022 Consider early vascular access. \u2022 Place on cardiac monitor. Obtain capnography, monitoring waveform and numerical value as clinically indicated . \u2022 Monitor and assess patient vital signs prior to administration of any analgesic. \u2022 For treatment of pain as needed with a blood pressure of greater than 100 systolic: \uf0d8 Fentanyl per ICEMA Reference # 11010 - Medication - Standard Orders (adult or pediatric patients) , for moderate to severe pain 6- 10 on pain scale or PAIN MANAGEMENT \u2013 ADULT and PEDIATRIC Reference No. 14100 Effective Date: 05/01/2 4 Supersedes: 04/01/23 Page 2 of 2 \uf0d8 Ketamine per ICEMA Reference # 11010 - Medication - Standard Orders (Adult Only- 15 Years of Age and Older ), for moderate to severe pain 6- 10 on pain scale or \uf0d8 Tylenol per ICEMA Reference # 11010 - Medication - Standard Orders (adult or pediatric patients) , for mild to moderate pain 1-5 on pain scale or in moderate to severe pain where other medications are contraindicated of deferred. \u2022 For treatment of pain as needed with a blood pressure less than 100 systolic: \uf0d8 Ketamine per ICEMA Reference # 11010 - Medication - Standard Orders, (Adult Only- 15 Years of Age and Older) for moderate to severe pain 6- 10 on pain scale or \uf0d8 Tylenol per ICEMA Reference # 11010 - Medication - Standard Orders (adult or pediatric patients) , for mild to moderate pain 1- 5 on pain scale or in moderate to severe pain where other medications are contraindicated or deferred. \u2022 Continuous monitoring of patients ECG and capnography is required for administration of Ketamine or fentanyl . \u2022 Reassess and document vital signs, capnography, and pain scores every five (5) minutes. V. SPECIAL CONSIDERATIONS \u2022 Shifting from one analgesic while treating a patient requires base hospital contact. VI. REFERENCES Number Name 11010 Medication - Standard Orders 11020 Procedure- Standard Order 14240 Suspected Acute Myocardial Infarction (AMI) 14070 Burns - Adult 14090 Trauma- Adult 14190 Burns -Pediatric 14180 Trauma- Pediatric 13030 Cold Related Emergencies"
  }
]